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Abstract
Objective: To assess the efficacy and safety of the anti-interleukin QR: dual variable 
domain immunoglobulin lutikizumab (ABT-981) in subjects with knee osteoarthritis (OA) and 
evidence of synovitis.
Methods: Subjects (N=350; 347 analyzed) with Kellgren-Lawrence grade 23 knee OA and 
synovitis (determined by magnetic resonance imaging [MRI] or ultrasound) were randomized to 
placebo or lutikizumab 25, 100 or 200 mg subcutaneously every 2 weeks for 50 weeks. The co-
primary endpoints were change from baseline in Western Ontario and McMaster Universities 
Osteoarthritis (WOMAC) pain index at week 16 and change from baseline in MRI synovitis at 
week 26. 
Results: WOMAC pain at week 16 improved significantly versus placebo with lutikizumab 100 
mg (P=0.050) but not 25 or 200 mg. Beyond week 16, WOMAC pain was reduced in all groups 
but was not significantly different for lutikizumab and placebo. Changes from baseline in MRI 
synovitis at week 26 and other key symptom- and most structure-related endpoints at weeks 26 
and 52 were not significantly different for lutikizumab and placebo. Injection site reactions, 
neutropenia, and discontinuations due to neutropenia were more frequent with lutikizumab 
versus placebo. Neutrophil and high-sensitivity C-reactive protein reductions plateaued at 
lutikizumab 100 mg. Immunogenicity to lutikizumab did not meaningfully affect systemic 
lutikizumab concentrations.
Conclusion: The limited improvement of WOMAC pain and the lack of synovitis improvement 
with lutikizumab, together with published trial results for other IL-1 inhibitors, suggest that IL-1 
inhibition is not an effective analgesic/anti-inflammatory therapy in most patients with knee OA 
and associated synovitis.
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INTRODUCTION
Osteoarthritis (OA) is the most common arthritis,(1) and main cause of disability among US 
adults.(2) OA is commonly considered a non-inflammatory arthritis but at least half of patients 
with knee OA have ultrasound or magnetic resonance imaging (MRI) evidence of synovitis.(3, 4) 
Synovitis is associated with a risk of developing radiographic knee OA,(5, 6) greater knee 
pain,(7, 8) and total joint replacement.(9)
Interleukin (IL) and : are pro-inflammatory cytokines and pain mediators that are 
thought to be involved in the pathogenesis of OA.(10, 11) : is secreted by innate immune 
cells after cleavage by caspase-1.(10) In contrast, : is stored intracellularly or membrane 
bound,(10) is released in an active form upon cell damage,(11) and can induce : activation 
and production of other cytokines important in the pathogenesis of OA.(10) : and : 
bind to the same receptor, IL-1R1, resulting in inflammatory and pain responses.(10, 12, 13)
: and : are expressed in the cartilage and synovial membrane, and are elevated in sera 
and synovial fluid in patients with OA.(14-16) Synovial macrophages are an important source of 
IL-1 in patients with knee OA.(17) IL-1 may promote structural damage associated with OA, 
because IL-1 activates enzymes involved in cartilage destruction,(18) inhibits collagen 
synthesis,(19) and promotes osteoclastogenesis.(10, 20) The IL-1 pathway may mediate OA pain 
through pathways in the peripheral and central nervous systems.(12, 13) In some, but not all 
animal models of OA, blocking the IL-1 pathway improves OA manifestations.(21) However, in 
clinical trials in subjects with knee OA not selected for synovitis, an IL-1 receptor antagonist 
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(anakinra)(22) or an antibody to the IL-1R1 (AMG 108)(23) did not meet the primary symptom-
based study endpoints.
Lutikizumab (ABT-981) is a novel human dual variable domain immunoglobulin (DVD-Ig) that 
has been shown to bind and inhibit : and :)(24) In mouse OA models, a mouse antiIL-
 DVD-Ig increased the threshold for pain and reduced cartilage degeneration to a greater 
extent than inhibition of either : or : alone.(25) In phase 1 studies of V9 weeks in 
healthy subjects and subjects with knee OA, single and multiple doses of lutikizumab were well 
tolerated; the most frequently reported adverse events (AEs) were injection site reactions and 
headache.(26, 27) Among the knee OA subjects in a phase 1 study, lutikizumab therapy was 
associated with reductions in serum inflammatory biomarkers.(27)
The current trial enrolled subjects with knee OA and MRI and/or ultrasound evidence of 
synovitis, a population presumed to be at high risk of progression, to test the hypothesis that dual 
inhibition of : and : would demonstrate efficacy and safety in knee OA with 
inflammation.
METHODS
Study Design
The objective was to determine the efficacy and safety of lutikizumab in subjects with knee OA 
and synovitis. The study was conducted in accordance with International Conference on 
Harmonization guidelines and the Declaration of Helsinki. This phase 2, randomized, double-
blind, placebo-controlled, parallel-group study (NCT02087904; ILLUSTRATE-K) was approved 
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by institutional review boards, and signed informed consent was obtained from all subjects. After 
screening and washout periods totaling approximately 45 days (Supplemental Figure 1), 
eligible subjects were randomized (1:1:1:1) to double-blind lutikizumab 25, 100, or 200 mg or 
matching placebo subcutaneously every 2 weeks for 52 weeks (last dose of study medication, 
week 50).
Rescue medication included acetaminophen (maximum, 3000 mg/d) during the washout period 
through week 26, and ibuprofen (maximum, 1200 mg/d), with or without acetaminophen, during 
weeks 16 to 26 for breakthrough knee pain, although analgesics were stopped W19 hours before 
the first dose of study drug and 24 hours before each pain assessment. From weeks 26 to 52, oral 
standard-of-care (SOC) medications for knee OA including non-steroidal anti-inflammatory 
drugs (NSAIDs), non-opioid analgesics, and nutraceuticals (e.g., glucosamine, chondroitin 
sulfate, shark cartilage, diacerein, soy extract) were permitted; SOC medications for knee OA 
were stopped W	1 hours before each pain assessment.
Subjects
Adult subjects (3574 years old) with radiographic evidence of knee OA in the medial 
compartment of the index knee with Kellgren-Lawrence (KL) grade 2 or 3(28) were eligible if 
meeting other inclusion criteria including signs and symptoms of active inflammation (e.g., 
localized pain, stiffness, swelling, or effusion) in the index knee; presence of synovitis in the 
index knee by either ultrasound (local reader, per an ultrasound guide) or MRI (central reader); 
pain score W1 and V9 (11-point numeric rating scale [NRS-11], 010 representing no pain to 
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worst possible pain)(29) in the index knee for W1 days over the past 30 days; and patient global 
assessment of arthritis status W1 (NRS-11, 010 representing best to worst disease status).(30)
Key exclusion criteria included other inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic 
arthritis, or gout) or a painful myofascial syndrome such as fibromyalgia (Supplemental 
Methods). 
Subjects must have discontinued use of all analgesics, NSAIDs, and nutraceuticals for W3 half-
lives of the longest-acting therapy or 48 hours, whichever was longer, before the first dose of 
study drug. Subjects receiving concomitant medications for indications other than OA (if 
allowed by the protocol) had to be on stable doses for W month before the first dose of study 
drug.
Efficacy
The co-primary endpoints were (1) change from baseline in Western Ontario and McMaster 
Universities Osteoarthritis index (WOMAC) pain score (050 scale; NRS-11 subscales)(31) at 
week 16 and (2) change in MRI synovitis from baseline in the index knee at week 26. To meet 
the latter co-primary endpoint , we required reductions in all 3 of the following measurements: 
(a) quantitative synovial membrane thickness,(32) (b) quantitative synovial fluid volume,(33) 
and (c) semi-quantitative synovitis/effusion score measured on a scale of 0 to 3 using the Whole-
Organ Magnetic Resonance Imaging Score (WORMS).(34) 
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Secondary endpoints included changes from baseline in WOMAC pain scores at weeks 26 and 
52(31); Intermittent and Constant Pain (ICOAP) score(35) at weeks 16, 26 and 52; and 3 types of 
pain intensity measures using NRS-11 scales (Supplemental Methods).
Exploratory endpoints included Outcome Measures in Rheumatology Clinical 
Trials/Osteoarthritis Research Society International (OMERACT/OARSI) response(36) at weeks 
16, 26 and 52; radiographic medial and lateral joint space narrowing (JSN; centralized 
measurement of the minimum joint space width compared with baseline in the index knee at 
week 52; and changes from baseline to week 26 in synovitis as assessed by dynamic contrast-
enhanced MRI (DCE-MRI).(37)
Imaging
Patients were screened for presence of synovitis using MRI or musculoskeletal ultrasound 
(Supplemental Methods), which has shown good to excellent inter- and intra-reader agreement 
in detecting knee synovitis.(38, 39) Posteroanterior weight-bearing radiographs of the target knee 
were acquired at screening and at week 52. MRI of the target knee was performed using 1.5- or 
3.0-T whole-body scanners and commercial knee coils at screening, week 26, and week 52. 
Given the limitations associated with noncontrast-enhanced MRI for assessment of synovitis,(8) 
dynamic contrast-enhanced MRI (DCE-MRI) was performed as an exploratory substudy (n=39), 
as described previously.(37) 
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Pharmacokinetics
Blood samples were collected throughout the 52 weeks to assess concentrations of lutikizumab 
and anti-drug antibody (ADA) responses in serum as previously described.(26)
Pharmacodynamics
Blood neutrophil counts and serum high-sensitivity C-reactive protein (hsCRP) levels (ICON, 
ARCHITECT platforms C8000 or C16000, Abbott Laboratories, Abbott Park, IL, United States) 
were measured repeatedly from baseline to week 52; other biomarkers were measured at baseline 
and weeks 16, 26 and 52. Serum concentrations of free : and : were determined using 
the Singulex Erenna (MilliporeSigma, Billerica, MA, United States) and SIMOA platforms 
(Quanterix, Lexington, MA, United States), respectively, using AbbVie proprietary capture and 
detection antibodies. Other biomarkers were measured by BioClinica Molecular Marker Lab 
(Lyon, France) using validated enzyme-linked immunosorbent assays (from Nordic Bioscience 
[Herlev, Denmark; metalloproteinase-degraded collagen types I and III and matrix 
metalloproteinase-generated fragment of CRP], Corgenix [Broomfield, CO, United States; 
hyaluronic acid], EMD Millipore [Darmstadt, Germany; N-propeptide of collagen IIA], and 
Roche Diagnostics [Indianapolis, IN, United States; C-terminal telopeptide fragments of type II 
collagen]), adhering to standard operating procedures from regulatory guidance for clinical 
studies.
Safety
Adverse events, vital signs, physical examinations, and laboratory data were assessed throughout 
the study. AEs were coded using the Medical Dictionary for Regulatory Activities, version 19.0, 
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preferred term, and system organ class. AE severity was classified according to the Common 
Terminology Criteria for Adverse Events, version 4.03.(40)
Statistics and Analyses
The co-primary and secondary efficacy outcomes were analyzed in the modified intent-to-treat 
population, comprising randomized patients who received W dose of study drug. Continuous 
efficacy assessments were analyzed with analysis of covariance (ANCOVA) with main factors of 
treatment, age group, and KL grade and covariates of baseline values, except analysis of daily 
rescue medication use, which was analyzed with analysis of variance (ANOVA). Categorical 
variables analysis used the Cochran-Mantel-Haenszel test with age group and KL grade as 
stratification factors. Last-observation-carried-forward (LOCF) imputation of missing values was 
used for non-imaging co-primary and selected secondary endpoints. The non-imaging co-
primary endpoint was also assessed using multiple imputation (MI) for missing values in a post 
hoc analysis. In this phase 2 study, there was no adjustment for multiplicity of assessments. The 
safety analysis set included subjects who received W dose of study drug. To identify factors 
associated with the development of neutropenia (defined as at least one episode where absolute 
neutrophil count [ANC] <1,500 cells/µL), explanatory variables significant at the P<0.1 level in 
univariate analyses were tested in a multiple logistic regression model.
A sample size of approximately 80 subjects per treatment group was estimated to provide W9<Z 
power to detect a significant difference between lutikizumab and placebo, based on a 
significance level of 0.05, for each of the two co-primary endpoints (WOMAC pain and synovial 
inflammation based on synovial membrane thickness by MRI). 
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RESULTS
Subjects
Of 1571 subjects screened, 350 were eligible and were randomized; 347 received W dose of 
study drug (June 2014 to November 2016) and were analyzed for efficacy and safety (Figure 1). 
The most common reasons for screen failure were clinical history related to entry criteria, 
absence of KL-2 or KL-3 radiographic evidence of knee OA, lack of synovitis on ultrasound or 
by noncontrast-enhanced MRI, and severe knee malalignment.(41) Most subjects (229; 65.4%) 
were enrolled based on ultrasound evidence of knee synovitis; 118 (33.7%) were enrolled based 
on MRI evidence (Supplemental Table 1). Among the subjects enrolled based solely on 
screening ultrasound, 185/220 (84.1%) had baseline MRI evidence of synovitis per WORMS 
scoring conducted at the end of the study. Demographics, baseline disease characteristics, and 
use of medications were generally well matched across treatment groups (Table 1). Of the 
randomized subjects, 60/85 (70.6%) who received placebo and 202/265 (76.2%) who received 
lutikizumab completed the 52-week study (Figure 1). The major reasons for discontinuation 
included AEs, lack of efficacy, and withdrawal of consent.
Efficacy
Co-primary Endpoints
The co-primary endpoint of WOMAC pain at week 16 (and at most early time points) improved 
significantly, compared with placebo, for the lutikizumab 100 mg dose group (P=0.050) but not 
for the lutikizumab 25 mg (P=0.834) and 200 mg (P=0.415) dose groups (Figure 2A, Table 2, 
Supplemental Figure 2A). Post hoc analysis for WOMAC pain using MI yielded results 
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consistent with those of LOCF (Supplemental Figure 3). WOMAC pain reduction in all 
lutikizumab groups, as well as placebo, was sustained from weeks 16 to 52, but differences 
between lutikizumab and placebo for WOMAC pain were not significant between weeks 16 and 
52 (Figure 3A). 
The other co-primary endpoint, change in synovitis (as measured by synovial membrane 
thickness, synovial fluid volume, and WORMS synovitis/effusion score) from baseline to week 
26, did not differ between the lutikizumab and placebo groups (Table 2). 
Post hoc analyses were performed to determine efficacy including only subjects with a baseline 
WORMS synovitis/effusion score >0, indicating MRI evidence of synovitis. Results in this post 
hoc population were not substantially different from those in the original, prospective population 
enrolled on the basis of positive MRI or ultrasound (Supplemental Figure 4, Supplemental 
Table 2).
Other Signs and Symptoms Endpoints
WOMAC function (Figure 2B, Supplemental Figure 2B) and OMERACT/OARSI response 
were numerically better but not significantly different between the placebo and lutikizumab 
treatment groups (Table 2) at 16, 26 and 52 weeks. Change from baseline in WOMAC function 
was significantly different (PV<)<R from placebo with lutikizumab 100 mg at weeks 4 and 8 
(Figure 2B). OMERACT/OARSI placebo responses were high, e.g., 60%71%, at weeks 26 and 
52, respectively (Table 2, Figure 2).
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Other Structural Endpoints
Among secondary and exploratory endpoints, other than medial (P=0.017) and lateral (P=0.005) 
JSN with lutikizumab 25 mg at week 52 (Table 2), there were no structural endpoints 
statistically significantly different between placebo and the lutikizumab dose groups. MRI 
assessments of cartilage volume, thickness, and WORMS scores were nearly identical in all 
treatment groups at baseline, week 26 and week 52. Synovitis, as assessed by DCE-MRI, also 
demonstrated no differences between subjects treated with placebo versus each dose of 
lutikizumab (Supplemental Table 3).
Rescue Medication Use
The proportion of subjects receiving concomitant pain medication (acetaminophen, ibuprofen) 
during the study was generally similar among treatment groups (Supplemental Table 4). The 
least squares mean daily dose of rescue acetaminophen up to week 16 was similar in the placebo 
(511 mg, n=58) and lutikizumab 25 mg (500 mg, n=53), 100 mg (413 mg, n=63) and 200 mg 
(426 mg, n=67) dose groups. Similarly, the least squares mean daily dose of rescue ibuprofen 
between weeks 16 and 26 was not significantly different between the placebo (200 mg, n=18) 
and lutikizumab 25 mg (104 mg, n=18), 100 mg (241 mg, n=19), and 200 mg (155 mg, n=24) 
dose groups. 
Pre-planned Efficacy Subgroup Analyses
In pre-planned subgroup analyses, there were no meaningful differences in WOMAC pain scores 
at weeks 16, 26, and 52 based on age, gender, race, or body weight. In the 100 mg dose group, 
there were statistically significantly greater decreases in WOMAC pain scores compared with 
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placebo, among subjects with an index knee KL grade of 3 (but not KL grade of 2) (week 26, 
P=0.029; week 52, 0.016) and among subjects who did not use concomitant medications for 
index knee pain through week 26 (week 16, P=0.027; week 26, 0.045). This was not noted in the 
25 mg or 200 mg dose group.
Pharmacokinetics
Lutikizumab trough concentrations were stable between weeks 6 and 52 and consistent with 
assessments of steady-state in previous studies (Supplemental Figure 5A).(26, 42) A greater 
ADA incidence was observed for the lutikizumab 25 mg dose group (46%) compared with the 
100 mg and 200 mg dose groups (32% and 23%, respectively). Lutikizumab serum 
concentrations were generally similar among subjects with and without ADAs for each dose 
group (Supplemental Figure 5B); thus, the immunogenic response did not appear to have a 
meaningful impact on lutikizumab pharmacokinetics.
Pharmacodynamics
Mean blood neutrophil counts (ANC) decreased with lutikizumab 100 mg and 200 mg treatment 
at all time points and with lutikizumab 25 mg at most time points relative to baseline and placebo 
(Figure 3A); neutrophil counts were similar in the 100 mg and 200 mg dose groups throughout 
the study. There was an exposure-response relationship between ANCs and lutikizumab blood 
levels (Supplemental Figure 6). In a similar way, hsCRP levels were reduced at most time 
points in the lutikizumab groups compared with baseline and placebo (Figure 3B), reaching 
statistical significance at several time points for the 25 mg and 100 mg doses but with high 
variability. 
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Serum levels of : and : at baseline were low and most were below the lower limits of 
quantification. In subjects with detectable levels at baseline, : and : levels were reduced 
within 2 weeks of treatment initiation to a greater extent in subjects receiving lutikizumab 
compared with subjects receiving placebo (Supplemental Figure 7, Supplemental Table 5). 
Changes in other biomarkers are shown in Supplemental Figure 8. With lutikizumab treatment, 
compared with placebo, there were reductions in metalloproteinase-degraded collagen type I 
(C1M), metalloproteinase-degraded collagen type III (C3M), matrix metalloproteinase-generated 
fragment of CRP (CRPM), IL-6, and alkaline phosphatase.
Safety
Similar proportions of subjects receiving placebo or lutikizumab experienced a treatment-
emergent AE or serious AE during the study (Table 3). Serious infections were infrequent and 
had similar incidences among treatment groups, including placebo. A greater proportion of 
subjects in the lutikizumab total treatment groups compared with the placebo group had injection 
site reactions (25.2% vs 15.3%) and neutropenia (27.5% vs 2.4%). The incidence of both events 
increased in a dose-dependent manner. All reported neutropenia laboratory abnormalities were 
grade 3 or less; there was no grade 4 neutropenia. One subject who received lutikizumab 25 mg 
and 6 subjects who received lutikizumab 200 mg discontinued study treatment because of 
neutropenia.
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Treatment-emergent AEs of malignancy were reported in 5 subjects (1.9%; 2.2 events per 100 
patient-years) in the total lutikizumab group and in no subjects in the placebo group. Basal cell 
carcinoma was reported in 3 of these 5 subjects. 
DISCUSSION
This study assessed the efficacy and safety of blocking : and : with lutikizumab in 
subjects with knee OA and associated synovitis. To our knowledge, this is the first study to test 
the hypothesis that a systemic anti-inflammatory, anti-cytokine therapy may be effective in knee 
OA patients with synovitis. Lutikizumab met the co-primary clinical endpoint of reduction in 
WOMAC pain compared with placebo at week 16 in only the 100 mg dose group, but not in the 
25 mg and 200 mg dose groups, and the differences compared with placebo were not sustained 
past week 16 for any dose. In the subgroup of patients treated with lutikizumab 100 mg with KL 
grade 3 knee OA and among the subgroup of subjects not using rescue or off-protocol pain 
medications, compared with placebo, the change from baseline at weeks 26 and 52 in WOMAC 
pain was significantly greater; the reason why this occurred only in the 100 mg dose group and 
only at these time points is unclear. The co-primary endpoint, change from baseline in synovitis 
as measured by synovial membrane thickness, synovial effusion volume, and semiquantitative 
MRI synovitis/effusion (WORMS) at week 26, was also not significantly different for 
lutikizumab versus placebo. Furthermore, when compared with placebo, lutikizumab was not 
associated with improvements or slowing in the rates of JSN and MRI cartilage thickness 
changes. These results indicate that lutikizumab had no significant impact on structural endpoints 
that were assessed. The analytical assay used to quantify lutikizumab serum concentrations 
required at least one free binding site for each molecule of : and :)(26) The modest 
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impact of ADAs on trough concentrations (Supplemental Figure 5B) suggested that 
development of ADAs did not interfere with the biological activity of lutikizumab, and thus they 
were unlikely to have impacted efficacy.
The unexpected lack of an effect of IL-1 inhibition on synovitis may signify that, although the 
synovium is an important source of IL-1,(43) IL-1 by itself may not be required to sustain 
synovitis. Other factors, such as cartilage degradation products and adipokines may have a 
greater role in the development and maintenance of synovitis.(44) Overall, these observations are 
consistent with a recent study using a medial menisectomy animal model that found that IL-1 
may not play a role in the structural progression of OA.(21) A phase 2 study of lutikizumab in 
erosive hand OA also was negative.(42)
The reason(s) for the failure to demonstrate a sustained beneficial analgesic effect of lutikizumab 
compared with placebo in this study is not clear. Lutikizumab serum concentrations were stable 
throughout the duration of the study, unaffected by development of ADAs and at exposures 
consistent with a previous phase 1 study.(27) The probability of achieving positive results might 
have been improved by using a flare study design, although a difference in effect size has not 
been shown to be statistically significant versus a non-flare study design.(45) Although serum 
: and : levels could not be reliably quantified, similar reductions in absolute neutrophil 
count and hsCRP between the lutikizumab 100 mg and 200 mg dose groups suggested that both 
dose groups achieved maximum suppression of : and :) However, it is possible that 
these systemic pharmacodynamic endpoints are not reflective of target engagement within the 
joint. 
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As there was no positive control treatment in this study, it is not clear whether lutikizumab did 
have a positive effect masked by a placebo response. The use of SOC therapies following week 
26 may have masked any lutikizumab treatment effects and could account for the lack of 
sustained WOMAC pain differences between the lutikizumab 100 mg treatment group and the 
placebo group, but would not explain the inefficacy of the 25 mg and 200 mg doses. The pre-
planned subset analyses suggested that the use of rescue medication affected the WOMAC pain 
co-primary endpoint results; however, meta-analysis has concluded that acetaminophen has little 
if any analgesic effect in OA.(46) Another pre-planned subset analysis suggested that subjects 
with KL grade 3 knee OA (in contrast to subjects with KL grade 2 knee OA) had statistically 
significant WOMAC pain treatment effects, implying that knee OA subjects with greater 
amounts of structural disease may benefit from IL-1 inhibition. The hypothesis that the 
concomitant use of pain medication and the degree of radiographic damage could predict 
response to lutikizumab would have to be proven in a well-designed prospective study. 
The lack of a clear lutikizumab treatment effect may have also been due to a strong, sustained 
placebo effect (Figure 3A). Placebo response rates are high in knee OA trials (e.g., 40%50% 
using OMERACT-OARSI criteria)(47); placebo response rates in this trial were 60%, 62% and 
71% at weeks 16, 26 and 52 (Table 2). High placebo responses have been reported in studies of 
injectable drugs.(48) 
There were no unexpected AEs compared with other IL-1 inhibitors,(23) except that there were 5 
malignancies in the combined lutikizumab treatment groups versus no malignancies in the 
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placebo group. While immunosuppression is associated with a risk of malignancy, two published 
studies of IL-1 inhibitors (CANTOS and RESURGE) have not identified an increased risk of 
malignancies.(49, 50) The CANTOS study of subjects treated with the : inhibitor 
canakinumab identified a significantly lower risk of incident lung cancer.(49) Given the 
CANTOS and RESURGE study data and the low numbers of malignancies observed in our 
study, it is currently unclear how best to interpret the greater number of malignancies in the 
combined lutikizumab treatment groups compared with the placebo group. Any future studies of 
lutikizumab should carefully monitor the incidence of malignancy to determine whether the 
findings observed in the present study are replicated.
Strengths of this study include the measurement of efficacy and pharmacodynamic endpoints in 
the same subjects. Plateauing of neutrophil decreases from baseline between the lutikizumab 100 
mg and 200 mg dose groups suggested that systemic IL-1 was maximally suppressed; similar 
reductions in neutrophil levels were achieved with the IL-1R inhibitor AMG 108.(23) Another 
strength was enrichment for subjects with evidence of inflammation using ultrasound, MRI, and 
clinical characteristics, with the assumption that this increased the likelihood of treating subjects 
with elevated joint levels of IL-1. Multiple signs and symptoms and structural endpoints were 
evaluated over 52 weeks, which maximized the opportunity to demonstrate an effect of 
lutikizumab. Confounding by other potentially disease-modifying agents was minimal. Further 
investigation could probe whether subgroups of patients with knee OA have a significant clinical 
response to lutikizumab.
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Several limitations of this study should be noted. Importantly, levels of lutikizumab, : and 
: in the synovial fluid of the knee joint could not be assessed. In addition, approximately 
two-thirds of subjects had relatively mild radiographic changes (KL-2, 62.8%) and none had 
severe disease (KL-4, 0%). Studies of tanezumab, a monoclonal antibody that targets nerve 
growth factor, enrolled a higher percentage of subjects with KL-3 and KL-4 disease (38.6%
46.9% and 14.1%27.7%, respectively),(47, 51) suggesting that patients with more severe 
disease may be more responsive to treatment, consistent with the pre-planned sub-analysis of 
subjects with KL grade 3 in the present study. This suggests that, by enrolling subjects with a 
lower average KL grade, the likelihood of observing significant pain improvements may have 
been reduced in the current study. As noted previously, a robust placebo response was found, 
possibly enriched by the allowance of rescue pain medication and the frequent study visits with 
subcutaneous drug administration. Another potential limitation of our study was highlighted by 
the discrepancy between ultrasound and MRI grading of synovitis. Of the limited number of 
cases (n=6) where an ultrasound and MRI were both submitted to screen for synovitis prior to 
enrollment, all 6 subjects were positive by ultrasound and only 3 of the 6 were positive by non
contrast-enhanced MRI, supporting the idea that the lack of contrast-enhancement may have 
limited our ability to detect changes in synovitis with lutikizumab therapy.
In conclusion, although the 100 mg dose of lutikizumab met the co-primary endpoint of 
reduction in WOMAC pain at week 16 compared with placebo, neither the 25 mg nor the 200 mg 
dose did so, and the difference from placebo was not sustained after week 16. Measures of 
synovitis, cartilage thickness, and other structural endpoints were similar between lutikizumab 
and placebo at all time points and with all 3 doses evaluated. The safety profile of lutikizumab 
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was consistent with the AEs reported for other IL-1 inhibitors, including neutropenia and 
injection site reactions. The results of this study suggest that IL-1 inhibition is not an effective 
disease-modifying therapy in patients with knee OA. Whether subgroups of knee OA patients 
might have symptomatic benefit from IL-1 inhibition remains an open question.
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Figure Legends
Figure 1. Patient disposition. Q2W, every 2 weeks; SC, subcutaneous. *Major protocol 
violations: (1) actual treatment is not according to randomization assignment, (2) premature 
unblinding, (3) use of a narcotic or non-steroidal anti-inflammatory drug for >50% of the days 
before week 16, (4) baseline index knee pain intensity <4 (11-point numeric rating scale), and (5) 
absence of synovitis in the index knee by ultrasound or magnetic resonance imaging during 
screening. Study completion at 52 weeks.
Figure 2. LS mean change from baseline over time for WOMAC pain (A) and WOMAC 
function (B). LS, least squares; Q2W, every 2 weeks; WOMAC, Western Ontario and McMaster 
Universities Osteoarthritis index. *PV<)<3 vs placebo; PV<)< vs placebo.
Figure 3. Time course of mean total neutrophils (A) and mean hsCRP levels (B) from baseline 
(week 0) to week 52. hsCRP, high-sensitivity C-reactive protein; Q2W, every 2 weeks. *P<0.05 
or a higher level of significance compared with placebo.
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Abstract
Objective: To assess the efficacy and safety of the anti-interleukin QR: dual variable 
domain immunoglobulin lutikizumab (ABT-981) in subjects with knee osteoarthritis (OA) and 
evidence of synovitis.
Methods: Subjects (N=350; 347 analyzed) with Kellgren-Lawrence grade 23 knee OA and 
synovitis (determined by magnetic resonance imaging [MRI] or ultrasound) were randomized to 
placebo or lutikizumab 25, 100 or 200 mg subcutaneously every 2 weeks for 50 weeks. The co-
primary endpoints were change from baseline in Western Ontario and McMaster Universities 
Osteoarthritis (WOMAC) pain index at week 16 and change from baseline in MRI synovitis at 
week 26. 
Results: WOMAC pain at week 16 improved significantly versus placebo with lutikizumab 100 
mg (P=0.050) but not 25 or 200 mg. Beyond week 16, WOMAC pain was reduced in all groups 
but was similar not significantly different for lutikizumab and placebo. Changes from baseline in 
MRI synovitis at week 26 and other key symptom- and most structure-related endpoints at weeks 
26 and 52 were not significantly differentsimilar for lutikizumab and placebo. Injection site 
reactions, neutropenia, and discontinuations due to neutropenia were more frequent with 
lutikizumab versus placebo. Neutrophil and high-sensitivity C-reactive protein reductions 
plateaued at lutikizumab 100 mg. Immunogenicity to lutikizumab did not meaningfully affect 
systemic lutikizumab concentrations.
Conclusion: The limited improvement of WOMAC pain and the lack of synovitis improvement 
with lutikizumab, together with published trial results for other IL-1 inhibitors, suggest that IL-1 
inhibition is not an effective analgesic/anti-inflammatory therapy in most patients with knee OA 
and associated synovitis.
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INTRODUCTION
Osteoarthritis (OA) is the most common arthritis,(1) and main cause of disability among US 
adults.(2) OA is commonly considered a non-inflammatory arthritis but at least half of patients 
with knee OA have ultrasound or magnetic resonance imaging (MRI) evidence of synovitis.(3, 4) 
Synovitis is associated with a risk of developing radiographic knee OA,(5, 6) greater knee 
pain,(7, 8) and total joint replacement.(9)
Interleukin (IL) and : are pro-inflammatory cytokines and pain mediators that are 
thought to be involved in the pathogenesis of OA.(10, 11) : is secreted by innate immune 
cells after cleavage by caspase-1.(10) In contrast, : is stored intracellularly or membrane 
bound,(10) is released in an active form upon cell damage,(11) and can induce : activation 
and production of other cytokines important in the pathogenesis of OA.(10) : and : 
bind to the same receptor, IL-1R1, resulting in inflammatory and pain responses.(10, 12, 13)
: and : are expressed in the cartilage and synovial membrane, and are elevated in sera 
and synovial fluid in patients with OA.(14-16) Synovial macrophages are an important source of 
IL-1 in patients with knee OA.(17) IL-1 may promote structural damage associated with OA, 
because IL-1 activates enzymes involved in cartilage destruction,(18) inhibits collagen 
synthesis,(19) and promotes osteoclastogenesis.(10, 20) The IL-1 pathway may mediate OA pain 
through pathways in the peripheral and central nervous systems.(12, 13) In some, but not all 
animal models of OA, blocking the IL-1 pathway improves OA manifestations.(21) However, in 
clinical trials in subjects with knee OA not selected for synovitis, an IL-1 receptor antagonist 
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(anakinra)(22) or an antibody to the IL-1R1 (AMG 108)(23) did not meet the primary symptom-
based study endpoints.
Lutikizumab (ABT-981) is a novel human dual variable domain immunoglobulin (DVD-Ig) that 
has been shown to bind and inhibit : and :)(24) In mouse OA models, a mouse antiIL-
 DVD-Ig increased the threshold for pain and reduced cartilage degeneration to a greater 
extent than inhibition of either : or : alone.(25) In phase 1 studies of V9 weeks in 
healthy subjects and subjects with knee OA, single and multiple doses of lutikizumab were well 
tolerated; the most frequently reported adverse events (AEs) were injection site reactions and 
headache.(26, 27) Among the knee OA subjects in a phase 1 study, lutikizumab therapy was 
associated with reductions in serum inflammatory biomarkers.(27)
The current trial enrolled subjects with knee OA and MRI and/or ultrasound evidence of 
synovitis, a population presumed to be at high risk of progression, to test the hypothesis that dual 
inhibition of : and : would demonstrate efficacy and safety in knee OA with 
inflammation.
METHODS
Study Design
The objective was to determine the efficacy and safety of lutikizumab in subjects with knee OA 
and synovitis. The study was conducted in accordance with the International Conference on 
Harmonization guidelines and the Declaration of Helsinki. This phase 2, randomized, double-
blind, placebo-controlled, parallel-group study (NCT02087904; ILLUSTRATE-K) was approved 
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by institutional review boards, and signed informed consent was obtained from all subjects. After 
screening and washout periods totaling approximately 45 days (Supplemental Figure 1), 
eligible subjects were randomized (1:1:1:1) to double-blind lutikizumab 25, 100, or 200 mg or 
matching placebo subcutaneously every 2 weeks for 52 weeks (last dose of study medication, 
week 50).
Rescue medication included acetaminophen (maximum, 3000 mg/d) during the washout period 
through week 26, and ibuprofen (maximum, 1200 mg/d), with or without acetaminophen, during 
weeks 16 to 26 for breakthrough knee pain, although analgesics were stopped W19 hours before 
the first dose of study drug and 24 hours before each pain assessment. From weeks 26 to 52, oral 
standard-of-care (SOC) medications for knee OA including non-steroidal anti-inflammatory 
drugs (NSAIDs), non-opioid analgesics, and nutraceuticals (e.g., glucosamine, chondroitin 
sulfate, shark cartilage, diacerein, soy extract) were permitted; SOC medications for knee OA 
were stopped W	1 hours before each pain assessment.
Subjects
Adult subjects (3574 years old) with radiographic evidence of knee OA in the medial 
compartment of the index knee with Kellgren-Lawrence (KL) grade 2 or 3(28) were eligible if 
meeting other inclusion criteria including signs and symptoms of active inflammation (e.g., 
localized pain, stiffness, swelling, or effusion) in the index knee; presence of synovitis in the 
index knee by either ultrasound (local reader, per an ultrasound guide) or MRI (central reader); 
pain score W1 and V9 (11-point numeric rating scale [NRS-11], 010 representing no pain to 
Page 50 of 131
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
13
worst possible pain)(29) in the index knee for W1 days over the past 30 days; and patient global 
assessment of arthritis status W1 (NRS-11, 010 representing best to worst disease status).(30)
Key exclusion criteria included other inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic 
arthritis, or gout) or a painful myofascial syndrome such as fibromyalgia (Supplemental 
Methods). 
Subjects must have discontinued use of all analgesics, NSAIDs, and nutraceuticals for W3 half-
lives of the longest-acting therapy or 48 hours, whichever was longer, before the first dose of 
study drug. Subjects receiving concomitant medications for indications other than OA (if 
allowed by the protocol) had to be on stable doses for W month before the first dose of study 
drug.
Efficacy
The co-primary endpoints were (1) change from baseline in Western Ontario and McMaster 
Universities Osteoarthritis index (WOMAC) pain score (050 scale; NRS-11 subscales)(31) at 
week 16 and (2) change in MRI synovitis from baseline in the index knee at week 26. To meet 
the latter co-primary endpoint , we required reductions in all 3 of the following measurements: 
(a) quantitative synovial membrane thickness,(32) (b) quantitative synovial fluid volume,(33) 
and (c) semi-quantitative synovitis/effusion score measured on a scale of 0 to 3 using the Whole-
Organ Magnetic Resonance Imaging Score (WORMS).(34) 
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Secondary endpoints included changes from baseline in WOMAC pain scores at weeks 26 and 
52(31); Intermittent and Constant Pain (ICOAP) score(35) at weeks 16, 26 and 52; and 3 types of 
pain intensity measures using NRS-11 scales (Supplemental Methods).
Exploratory endpoints included Outcome Measures in Rheumatology Clinical 
Trials/Osteoarthritis Research Society International (OMERACT/OARSI) response(36) at weeks 
16, 26 and 52; radiographic medial and lateral joint space narrowing (JSN; centralized 
measurement of the minimum joint space width compared with baseline in the index knee at 
week 52; and changes from baseline to week 26 in synovitis as assessed by dynamic contrast-
enhanced MRI (DCE-MRI).(37)
Imaging
Patients were screened for presence of synovitis using MRI or musculoskeletal ultrasound 
(Supplemental Methods), which has shown good to excellent inter- and intra-reader agreement 
in detecting knee synovitis.(38, 39) Posteroanterior weight-bearing radiographs of the target knee 
were acquired at screening and at week 52. MRI of the target knee was performed using 1.5- or 
3.0-T whole-body scanners and commercial knee coils at screening, week 26, and week 52. 
Given the limitations associated with noncontrast-enhanced MRI for assessment of synovitis,(8) 
dynamic contrast-enhanced MRI (DCE-MRI) was performed as an exploratory substudy (n=39), 
as described previously.(37) 
Page 52 of 131
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
15
Pharmacokinetics
Blood samples were collected throughout the 52 weeks to assess concentrations of lutikizumab 
and anti-drug antibody (ADA) responses in serum as previously described.(26)
Pharmacodynamics
Blood neutrophil counts and serum high-sensitivity C-reactive protein (hsCRP) levels (ICON, 
ARCHITECT platforms C8000 or C16000, Abbott Laboratories, Abbott Park, IL, United States) 
were measured repeatedly from baseline to week 52; other biomarkers were measured at baseline 
and weeks 16, 26 and 52. Serum concentrations of free : and : were determined using 
the Singulex Erenna (MilliporeSigma, Billerica, MA, United States) and SIMOA platforms 
(Quanterix, Lexington, MA, United States), respectively, using AbbVie proprietary capture and 
detection antibodies. Other biomarkers were measured by BioClinica Molecular Marker Lab 
(Lyon, France) using validated enzyme-linked immunosorbent assays (from Nordic Bioscience 
[Herlev, Denmark; metalloproteinase-degraded collagen types I and III and matrix 
metalloproteinase-generated fragment of CRP], Corgenix [Broomfield, CO, United States; 
hyaluronic acid], EMD Millipore [Darmstadt, Germany; N-propeptide of collagen IIA], and 
Roche Diagnostics [Indianapolis, IN, United States; C-terminal telopeptide fragments of type II 
collagen]), adhering to standard operating procedures from regulatory guidance for clinical 
studies.
Safety
Adverse events, vital signs, physical examinations, and laboratory data were assessed throughout 
the study. AEs were coded using the Medical Dictionary for Regulatory Activities, version 19.0, 
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preferred term, and system organ class. AE severity was classified according to the Common 
Terminology Criteria for Adverse Events, version 4.03.(40)
Statistics and Analyses
The co-primary and secondary efficacy outcomes were analyzed in the modified intent-to-treat 
population, comprising randomized patients who received W dose of study drug. Continuous 
efficacy assessments were analyzed with analysis of covariance (ANCOVA) with main factors of 
treatment, age group, and KL grade and covariates of baseline values, except analysis of daily 
rescue medication use, which was analyzed with analysis of variance (ANOVA). Categorical 
variables analysis used the Cochran-Mantel-Haenszel test with age group and KL grade as 
stratification factors. Last-observation-carried-forward (LOCF) imputation of missing values was 
used for non-imaging co-primary and selected secondary endpoints. The non-imaging co-
primary endpoint was also assessed using multiple imputation (MI) for missing values in a post 
hoc analysis. In this phase 2 study, there was no adjustment for multiplicity of assessments. The 
safety analysis set included subjects who received W dose of study drug. To identify factors 
associated with the development of neutropenia (defined as at least one episode where absolute 
neutrophil count [ANC] <1,500 cells/µL), explanatory variables significant at the P<0.1 level in 
univariate analyses were tested in a multiple logistic regression model.
A sample size of approximately 80 subjects per treatment group was estimated to provide W9<Z 
power to detect a significant difference between lutikizumab and placebo, based on a 
significance level of 0.05, for each of the two co-primary endpoints (WOMAC pain and synovial 
inflammation based on synovial membrane thickness by MRI). 
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RESULTS
Subjects
Of 1571 subjects screened, 350 were eligible and were randomized; 347 received W dose of 
study drug (June 2014 to November 2016) and were analyzed for efficacy and safety (Figure 1). 
The most common reasons for screen failure were clinical history related to entry criteria, 
absence of KL-2 or KL-3 radiographic evidence of knee OA, lack of synovitis on ultrasound or 
by noncontrast-enhanced MRI, and severe knee malalignment.(41) Most subjects (229; 65.4%) 
were enrolled based on ultrasound evidence of knee synovitis; 118 (33.7%) were enrolled based 
on MRI evidence (Supplemental Table 1). Among the subjects enrolled based solely on 
screening ultrasound, 185/220 (84.1%) had baseline MRI evidence of synovitis per WORMS 
scoring conducted at the end of the study. Demographics, baseline disease characteristics, and 
use of medications were generally well matched across treatment groups (Table 1). Of the 
randomized subjects, 60/85 (70.6%) who received placebo and 202/265 (76.2%) who received 
lutikizumab completed the 52-week study (Figure 1). The major reasons for discontinuation 
included AEs, lack of efficacy, and withdrawal of consent.
Efficacy
Co-primary Endpoints
The co-primary endpoint of WOMAC pain at week 16 (and at most early time points) improved 
significantly, compared with placebo, for the lutikizumab 100 mg dose group (P=0.050) but not 
for the lutikizumab 25 mg (P=0.834) and 200 mg (P=0.415) dose groups (Figure 2A, Table 2, 
Supplemental Figure 2A). Post hoc analysis for WOMAC pain using MI yielded results 
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consistent with those of LOCF (Supplemental Figure 3). WOMAC pain reduction in all 
lutikizumab groups, as well as placebo, was sustained from weeks 16 to 52, but differences 
between lutikizumab and placebo for WOMAC pain were not significant between weeks 16 and 
52 (Figure 3A). 
The other co-primary endpoint, change in synovitis (as measured by synovial membrane 
thickness, synovial fluid volume, and WORMS synovitis/effusion score) from baseline to week 
26, did not differ between the lutikizumab and placebo groups (Table 2). 
Post hoc analyses were performed to determine efficacy including only subjects with a baseline 
WORMS synovitis/effusion score >0, indicating MRI evidence of synovitis. Results in this post 
hoc population were not substantially different from those in the original, prospective population 
enrolled on the basis of positive MRI or ultrasound (Supplemental Figure 4, Supplemental 
Table 2).
Other Signs and Symptoms Endpoints
WOMAC function (Figure 2B, Supplemental Figure 2B) and OMERACT/OARSI response 
were numerically better but not significantly different between the placebo and lutikizumab 
treatment groups (Table 2) at 16, 26 and 52 weeks. Change from baseline in WOMAC function 
was significantly different (PV<)<R from placebo with lutikizumab 100 mg at weeks 4 and 8 
(Figure 2B). OMERACT/OARSI placebo responses were high, e.g., 60%71%, at weeks 26 and 
52, respectively (Table 2, Figure 2).
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Other Structural Endpoints
Among secondary and exploratory endpoints, other than medial (P=0.017) and lateral (P=0.005) 
JSN with lutikizumab 25 mg at week 52 (Table 2), there were no structural endpoints 
statistically significantly different between placebo and the lutikizumab dose groups. MRI 
assessments of cartilage volume, thickness, and WORMS scores were nearly identical in all 
treatment groups at baseline, week 26 and week 52. Synovitis, as assessed by DCE-MRI, also 
demonstrated no differences between subjects treated with placebo versus each dose of 
lutikizumab (Supplemental Table 32).
Rescue Medication Use
The proportion of subjects receiving concomitant pain medication (acetaminophen, ibuprofen) 
during the study was generally similar among treatment groups (Supplemental Table 43). The 
least squares mean daily dose of rescue acetaminophen up to week 16 was similar in the placebo 
(511 mg, n=58) and lutikizumab 25 mg (500 mg, n=53), 100 mg (413 mg, n=63) and 200 mg 
(426 mg, n=67) dose groups. Similarly, the least squares mean daily dose of rescue ibuprofen 
between weeks 16 and 26 was not significantly different between the placebo (200 mg, n=18) 
and lutikizumab 25 mg (104 mg, n=18), 100 mg (241 mg, n=19), and 200 mg (155 mg, n=24) 
dose groups. 
Pre-planned Efficacy Subgroup Analyses
In pre-planned subgroup analyses, there were no meaningful differences in WOMAC pain scores 
at weeks 16, 26, and 52 based on age, gender, race, or body weight. In the 100 mg dose group, 
there were statistically significantly greater decreases in WOMAC pain scores compared with 
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placebo, among subjects with an index knee KL grade of 3 (but not KL grade of 2) (week 26, 
P=0.029; week 52, 0.016) and among subjects who did not use concomitant medications for 
index knee pain through week 26 (week 16, P=0.027; week 26, 0.045). This was not noted in the 
25 mg or 200 mg dose group.
Pharmacokinetics
Lutikizumab trough concentrations were stable between weeks 6 and 52 and consistent with 
assessments of steady-state in previous studies (Supplemental Figure 5A3A).(26, 42) A greater 
anti-drug antibodyADA incidence was observed for the lutikizumab 25 mg dose group (46%) 
compared with the 100 mg and 200 mg dose groups (32% and 23%, respectively). Lutikizumab 
serum concentrations were generally similar among subjects with and without anti-drug 
antibodiesADAs for each dose group (Supplemental Figure 5B3B); thus, the immunogenic 
response did not appear to have a meaningful impact on lutikizumab pharmacokinetics.
Pharmacodynamics
Mean blood neutrophil counts (ANC) decreased with lutikizumab 100 mg and 200 mg treatment 
at all time points and with lutikizumab 25 mg at most time points relative to baseline and placebo 
(Figure 3A); neutrophil counts were similar in the 100 mg and 200 mg dose groups throughout 
the study. There was an exposure-response relationship between ANCs and lutikizumab blood 
levels (Supplemental Figure 64). In a similar way, hsCRP levels were reduced at most time 
points in the lutikizumab groups compared with baseline and placebo (Figure 3B), reaching 
statistical significance at several time points for the 25 mg and 100 mg doses but with high 
variability. 
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Serum levels of : and : at baseline were low and most were below the lower limits of 
quantification. In subjects with detectable levels at baseline, : and : levels were reduced 
within 2 weeks of treatment initiation to a greater extent in subjects receiving lutikizumab 
compared with subjects receiving placebo (Supplemental Figure 75, Supplemental Table 45). 
Changes in other biomarkers are shown in Supplemental Figure 86. With lutikizumab 
treatment, compared with placebo, there were reductions in metalloproteinase-degraded collagen 
type I (C1M), metalloproteinase-degraded collagen type III (C3M), matrix metalloproteinase-
generated fragment of CRP (CRPM), IL-6, and alkaline phosphatase.
Safety
Similar proportions of subjects receiving placebo or lutikizumab experienced a treatment-
emergent AE or serious AE during the study (Table 3). Serious infections were infrequent and 
had similar incidences among treatment groups, including placebo. A greater proportion of 
subjects in the lutikizumab total treatment groups compared with the placebo group had injection 
site reactions (25.2% vs 15.3%) and neutropenia (27.5% vs 2.4%). The incidence of both events 
increased in a dose-dependent manner. All reported neutropenia laboratory abnormalities were 
grade 3 or less; there was no grade 4 neutropenia. One subject who received lutikizumab 25 mg 
and 6 subjects who received lutikizumab 200 mg discontinued study treatment because of 
neutropenia.
A multiple logistic regression model was used to identify factors associated with the 
development of neutropenia. In addition to lutikizumab dose (P<0.0001), baseline neutrophil 
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count (odds ratio [OR], 0.19; 95% CI, 0.120.30; P<0.0001), age <62 (OR, 2.11; 95% CI, 1.09
4.09; P=0.027), and female sex (OR, 2.86; 95% CI, 1.346.10; P=0.007) were significantly 
associated with the development of neutropenia (Supplemental Table 5). Grade 3 or 4 
lymphopenia and hypertriglyceridemia occurred in a few subjects, without clear patterns; there 
was no grade 3 or 4 thrombocytopenia or hypercholesterolemia.
Treatment-emergent AEs of malignancy were reported in 5 subjects (1.9%; 2.2 events per 100 
patient-years) in the total lutikizumab group and in no subjects in the placebo group. Basal cell 
carcinoma was reported in 3 of these 5 subjects. 
DISCUSSION
This study assessed the efficacy and safety of blocking : and : with lutikizumab in 
subjects with knee OA and associated synovitis. To our knowledge, this is the first study to test 
the hypothesis that a systemic anti-inflammatory, anti-cytokine therapy may be effective in knee 
OA patients with synovitis. Lutikizumab met the co-primary clinical endpoint of reduction in 
WOMAC pain compared with placebo at week 16 in only the 100 mg dose group, but not in the 
25 mg and 200 mg dose groups, and the differences compared with placebo were not sustained 
past week 16 for any dose. In the subgroup of patients treated with lutikizumab 100 mg with KL 
grade 3 knee OA and among the subgroup of subjects not using rescue or off-protocol pain 
medications, compared with placebo, the change from baseline at weeks 26 and 52 in WOMAC 
pain was significantly greater; the reason why this occurred only in the 100 mg dose group and 
only at these time points is unclear. The co-primary endpoint, change from baseline in synovitis 
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as measured by synovial membrane thickness, synovial effusion volume, and semiquantitative 
MRI synovitis/effusion (WORMS) at week 26, was also not significantly different for 
lutikizumab versus placebo. Furthermore, when compared with placebo, lutikizumab was not 
associated with improvements or slowing in the rates of JSN and MRI cartilage thickness 
changes. These results indicate that lutikizumab had no significant impact on structural endpoints 
that were assessed. The analytical assay used to quantify lutikizumab serum concentrations 
required at least one free binding site for each molecule of : and :)(26) The modest 
impact of ADAs on trough concentrations (Supplemental Figure 5B3B) suggested that 
development of ADAs did not interfere with the biological activity of lutikizumab, and thus they 
were unlikely to have impacted efficacy.
The unexpected lack of an effect of IL-1 inhibition on synovitis may signify that, although the 
synovium is an important source of IL-1,(43) IL-1 by itself may not be required to sustain 
synovitis. Other factors, such as cartilage degradation products and adipokines may have a 
greater role in the development and maintenance of synovitis.(44) Overall, these observations are 
consistent with a recent study using a medial menisectomy animal model that found that IL-1 
may not play a role in the structural progression of OA.(21) A phase 2 study of lutikizumab in 
erosive hand OA also was negative.(42)
The reason(s) for the failure to demonstrate a sustained beneficial analgesic effect of lutikizumab 
compared with placebo in this study is not clear. Lutikizumab serum concentrations were stable 
throughout the duration of the study, unaffected by development of anti-drug antibodiesADAs 
and at exposures consistent with a previous phase 1 study.(27) The probability of achieving 
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positive results might have been improved by using a flare study design, although a difference in 
effect size has not been shown to be statistically significant versus a non-flare study design.(45) 
Although serum : and : levels could not be reliably quantified, similar reductions in 
absolute neutrophil count and hsCRP between the lutikizumab 100 mg and 200 mg dose groups 
suggested that both dose groups achieved maximum suppression of : and :) However, it 
is possible that these systemic pharmacodynamic endpoints are not reflective of target 
engagement within the joint. 
As there was no positive control treatment in this study, it is not clear whether lutikizumab did 
have a positive effect masked by a placebo response. The use of SOC therapies following week 
26 may have masked any lutikizumab treatment effects and could account for the lack of 
sustained WOMAC pain differences between the lutikizumab 100 mg treatment group and the 
placebo group, but would not explain the inefficacy of the 25 mg and 200 mg doses. The pre-
planned subset analyses suggested that the use of rescue medication affected the WOMAC pain 
co-primary endpoint results; however, meta-analysis has concluded that acetaminophen has little 
if any analgesic effect in OA.(46) Another pre-planned subset analysis suggested that subjects 
with KL grade 3 knee OA (in contrast to subjects with KL grade 2 knee OA) had statistically 
significant WOMAC pain treatment effects, implying that knee OA subjects with greater 
amounts of structural disease may benefit from IL-1 inhibition. The hypothesis that the 
concomitant use of pain medication and the degree of radiographic damage could predict 
response to lutikizumab would have to be proven in a well-designed prospective study. 
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The lack of a clear lutikizumab treatment effect may have also been due to a strong, sustained 
placebo effect (Figure 3A). Placebo response rates are high in knee OA trials (e.g., 40%50% 
using OMERACT-OARSI criteria)(47); placebo response rates in this trial were 60%, 62% and 
71% at weeks 16, 26 and 52 (Table 2). High placebo responses have been reported in studies of 
injectable drugs.(48) 
There were no unexpected AEs compared with other IL-1 inhibitors,(23) except that there were 5 
malignancies in the combined lutikizumab treatment groups versus no malignancies in the 
placebo group. While immunosuppression is associated with a risk of malignancy, two published 
studies of IL-1 inhibitors (CANTOS and RESURGE) have not identified an increased risk of 
malignancies.(49, 50) The CANTOS study of subjects treated with the : inhibitor 
canakinumab identified a significantly lower risk of incident lung cancer.(49) Given the 
CANTOS and RESURGE study data and the low numbers of malignancies observed in our 
study, it is currently unclear how best to interpret the greater number of malignancies in the 
combined lutikizumab treatment groups compared with the placebo group. Any future studies of 
lutikizumab should carefully monitor the incidence of malignancy to determine whether the 
findings observed in the present study are replicated.
Strengths of this study include the measurement of efficacy and pharmacodynamic endpoints in 
the same subjects. Plateauing of neutrophil decreases from baseline between the lutikizumab 100 
mg and 200 mg dose groups suggested that systemic IL-1 was maximally suppressed; similar 
reductions in neutrophil levels were achieved with the IL-1R inhibitor AMG 108.(23) Another 
strength was enrichment for subjects with evidence of inflammation using ultrasound, MRI, and 
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clinical characteristics, with the assumption that this increased the likelihood of treating subjects 
with elevated joint levels of IL-1. Multiple signs and symptoms and structural endpoints were 
evaluated over 52 weeks, which maximized the opportunity to demonstrate an effect of 
lutikizumab. Confounding by other potentially disease-modifying agents was minimal. Further 
investigation could probe whether subgroups of patients with knee OA have a significant clinical 
response to lutikizumab.
Several limitations of this study should be noted. Importantly, levels of lutikizumab, : and 
: in the synovial fluid of the knee joint could not be assessed. In addition, approximately 
two-thirds of subjects had relatively mild radiographic changes (KL-2, 62.8%) and none had 
severe disease (KL-4, 0%). Studies of tanezumab, a monoclonal antibody that targets nerve 
growth factor, enrolled a higher percentage of subjects with KL-3 and KL-4 disease (38.6%
46.9% and 14.1%27.7%, respectively),(47, 51) suggesting that patients with more severe 
disease may be more responsive to treatment, consistent with the pre-planned sub-analysis of 
subjects with KL grade 3 in the present study. This suggests that, by enrolling subjects with a 
lower average KL grade, the likelihood of observing significant pain improvements may have 
been reduced in the current study. As noted previously, a robust placebo response was found, 
possibly enriched by the allowance of rescue pain medication and the frequent study visits with 
subcutaneous drug administration. Another potential limitation of our study was highlighted by 
the discrepancy between ultrasound and MRI grading of synovitis. Of the limited number of 
cases (n=6) where an ultrasound and MRI were both submitted to screen for synovitis prior to 
enrollment, all 6 subjects were positive by ultrasound and only 3 of the 6 were positive by non
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contrast-enhanced MRI, supporting the idea that the lack of contrast-enhancement may have 
limited our ability to detect changes in synovitis with lutikizumab therapy.
In conclusion, although the 100 mg dose of lutikizumab met the co-primary endpoint of 
reduction in WOMAC pain at week 16 compared with placebo, neither the 25 mg nor the 200 mg 
dose did so, and the difference from placebo was not sustained after week 16. Measures of 
synovitis, cartilage thickness, and other structural endpoints were similar between lutikizumab 
and placebo at all time points and with all 3 doses evaluated. The safety profile of lutikizumab 
was consistent with the AEs reported for other IL-1 inhibitors, including neutropenia and 
injection site reactions. The results of this study suggest that IL-1 inhibition is not an effective 
disease-modifying therapy in patients with knee OA. Whether subgroups of knee OA patients 
might have symptomatic benefit from IL-1 inhibition remains an open question.
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Figure Legends
Figure 1. Patient disposition. Q2W, every 2 weeks; SC, subcutaneous. *Major protocol 
violations: (1) actual treatment is not according to randomization assignment, (2) premature 
unblinding, (3) use of a narcotic or non-steroidal anti-inflammatory drug for >50% of the days 
before week 16, (4) baseline index knee pain intensity <4 (11-point numeric rating scale), and (5) 
absence of synovitis in the index knee by ultrasound or magnetic resonance imaging during 
screening. Study completion at 52 weeks.
Figure 2. LS mean change from baseline over time for WOMAC pain (A) and WOMAC 
function (B). LS, least squares; Q2W, every 2 weeks; WOMAC, Western Ontario and McMaster 
Universities Osteoarthritis index. *PV<)<3 vs placebo; PV<)< vs placebo.
Figure 3. Time course of mean total neutrophils (A) and mean hsCRP levels (B) from baseline 
(week 0) to week 52. hsCRP, high-sensitivity C-reactive protein; Q2W, every 2 weeks. *P<0.05 
or a higher level of significance compared with placebo.
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Table 1. Demographics, Baseline Disease Characteristics, and Prior Medications
Lutikizumab SC Q2W, mg
Characteristic
Placebo 
(n=85) 25 (n=89) 100 (n=85) 200 (n=88)
Age, y
Women, n (%) 52 (61.2) 63 (70.8) 53 (62.4) 57 (64.8)
Race, n (%)
White 78 (91.8) 78 (87.6) 70 (82.4) 79 (89.8)
Black 4 (4.7) 8 (9.0) 10 (11.8) 7 (8.0)
Other 3 (3.5) 3 (3.4) 5 (5.9) 2 (2.3)
BMI, kg/m2
OA duration, y
KL grade,* n (%)
2 53 (62.4) 57 (64.0) 52 (61.2) 56 (63.6)
3 32 (37.6) 32 (36.0) 33 (38.8) 32 (36.4)
WOMAC total (scale 0240; higher 
scores indicate worse condition)
 
WOMAC pain (scale 050) 
WOMAC function (scale 0170)  
WOMAC stiffness (scale 020) 
Synovial membrane thickness, mm  §  
Synovial fluid volume, mL || ¶ #
WORMS semiquantitative 
synovitis/effusion (scale 03)
 
WORMS total (scale 0400; higher 
scores indicate worse condition)
  §§ ||
WORMS total BML (scale 045)    #
WORMS total osteophytes (scale  # ¶ 
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0112)
9/L (norma
109/L)
hsCRP, mg/L
Prior knee OA therapy, n (%)a     
NSAID 38 (44.7) 31 (34.8) 32 (37.6) 40 (45.5)
Intra-articular corticosteroid 1 (1.2) 1 (1.2) 0 0
Narcotic 4 (4.7) 3 (3.4) 2 (2.4) 3 (3.4)
Concomitant knee and systemic 
pain medication at baseline
79 (92.9) 70 (78.7) 71 (83.5) 78 (88.6)
Data are  where noted.
ANC, absolute neutrophil count; BMI, body mass index; BML, bone marrow lesions; hsCRP, 
high-sensitivity C-reactive protein; KL, Kellgren-Lawrence; NSAID, non-steroidal anti-
inflammatory drug; OA, osteoarthritis; Q2W, every 2 weeks; SC, subcutaneous; WOMAC, 
Western Ontario and McMaster Universities Osteoarthritis index; WORMS, Whole-Organ 
Magnetic Resonance Imaging Score.
*KL grade 2: definite osteophytes and possible joint space narrowing on anteroposterior weight-
bearing radiograph. KL grade 3: multiple osteophytes, definite joint space narrowing, sclerosis, 
possible bony deformity.
1, 9, 10,   7, 6, 2, **5, 3, 4, and 8 subjects with missing data.
     Prior or concomitant therapy with intra-articular hyaluronan was not excluded, and 1 subject 
reported prior hyaluronan therapy and 2 patients reported intra-articular hyaluronan therapy after 
the study started.
Subjects could have taken more than 1 kind of narcotic previously. Hydrocodone with 
acetaminophen (n=7), oxycodone (n=2), oxycodone with acetaminophen (n=2), codeine with 
acetaminophen (n=1), hydrocodone (n=1), and oxycodone with naloxone (n=1).
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n oints
Signs and  	
 oin
 t 
W  Week 52
Lutikizumab SC Q2W, mg Lutikizumab SC Q2W, mg
	E t  ff Pfi tflffi 25 (n=89) 100 (n=85) 200 (n=88) Pfi tflffi 25 (n=89) 100 (n=85) 200 (n=88)
Co-primary endpoint
WOMAC pain 
(050; higher scores 
indicate worse 
condition)
8.9
(11.0, 6.9)
9.2
(11.2, 7.2)
11.8
(13.8, 9.8)
10.1
(12.1, 8.1)
10.0
(12.2, 7.7)
11.0
(13.3, 8.8)
12.1
(14.4, 9.8)
12.2
(14.5, 10.0)
Difference vs PBO *#
*## 2.53)
*!
*"# 0.01)
*!
*$ 1.66)
*
*$!  2.08)
*!!
*# 1.05)
*!#
 *$  0.88)
P value vs PBO 0.834 0!00" 0.415 0.500 0.186 0.157
Secondary endpoint
WOMAC function 
(0170; higher scores 
indicate worse 
condition)
28.7
(35.3, 22.2)
29.8
(36.3, 23.3)
36.3
(42.9, 29.7)
32.1
(38.6, 25.6)
32.9
(40.7, 25.1)
36.1
(43.8, 28.5)
38.7
(46.5, 30.9)
39.7
(47.4, 32.0)
Difference vs PBO 1.1
*!! 8.08)
7.6
(16.83, 1.69)
3.4
(12.58, 5.76)
3.2
(14.03, 7.59)
5.8
(16.77, 5.11)
6.8
 (17.63, 4.04)
P value vs PBO 0.818 0.109 0.465 0.558 0.295 0.218
Exploratory endpoint
OMERACT/OARSI 
response, %
60.0
(49.6, 70.4)
67.0
(57.2, 76.9)
72.6
(63.1, 82.2)
65.5
(55.5, 75.5)
70.6
(60.9, 80.3)
69.3
(59.7, 79.0)
71.4
(61.8, 81.1)
72.7
(63.4, 82.0)
Difference vs PBO 7.0
(7.3, 21.4)
12.6
(1.5, 26.7)
5.5
(8.9, 19.9)
1.3
*$ 12.4)
0.8
(12.8, 14.5)
2.1
(11.3, 15.6)
P value vs PBO 0.311 0.080 0.435 0.824 0.964 0.763
 SffS 	E
 t$
eSr 
W % Week 52
Lutikizumab SC Q2W, mg Lutikizumab SC Q2W, mg
	E Pfi 25 100 200 Pfi 25 100 200
Co-primary endpoint
Synovial membrane 
thickness, mm
0.05
(0.11, 0.01)
0.01
(0.05, 0.07)
0.08
(0.13, 0.02)
0.01
(0.05, 0.07)
0.07
(0.14, 0.01)
0.04
(0.10, 0.02)
0.05
(0.11, 0.01)
0.02
(0.08, 0.05)
n 59 65 59 63 50 59 55 53
Difference vs PBO 0.06
(0.02, 0.14)
0.03
(0.11, 0.06)
0.06
(0.02, 0.14)
0.03
(0.06, 0.12)
0.02
(0.07, 0.11)
0.06
(0.03, 0.14)
P value vs PBO 0.145 0.520 0.159 0.474 0.637 0.221
Synovial fluid volume, 0.03 0.26 1.04 1.49 1.90 1.17 0.67 1.83
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mL (2.50, 2.56) (2.11, 2.62) (3.42, 1.35) (3.87, 0.90) (5.03, 1.23) (1.78, 4.12) (3.59, 2.25) (4.82, 1.16)
n 60 69 67 68 53 60 60 58
Difference vs PBO 0.22
(3.19, 3.64)
1.07
(4.52, 2.38)
1.52
(4.95, 1.92)
3.08
(1.16, 7.32)
1.23
(3.02, 5.49)
0.07
(4.21, 4.35)
P value vs PBO 0.897 0.542 0.385 0.154 0.569 0.973
WORMS 
semiquantitative 
synovitis/effusion 
volume
0.07
(0.06, 0.19)
0.01
(0.13, 0.11)
0.08
(0.21, 0.04)
0.07
(0.20, 0.05)
0.05
(0.18, 0.09)
0.05
(0.18, 0.08)
0.06
(0.19, 0.08)
0.01
(0.14, 0.12)
n 70 76 70 75 59 66 62 66
Difference vs PBO 0.08
(0.25, 0.10)
0.15
(0.32, 0.03)
0.14
(0.31, 0.03)
0.00
(0.19, 0.18) 
0.01
(0.20, 0.18)
0.04
(0.15, 0.22)
P value vs PBO 0.384 0.095 0.106 0.967 0.923 0.692
Secondary endpoint
Cartilage volume, 
mm3
n 58 65 53 66 49 57 50 56
Total *#! 
(400.8, 
*!
*#!
(397.1, 
*!#
*#!!$
(400.2, 
*!$$ 
*#
(429.7, 
*!$
*"
(659.9, 
*$$
*"
(694.7, 
*!
*$#
(654.9, 
*$# 
*#
(678.9, 
*$"!
Difference vs PBO 0.5
(101.6, 
102.6)
3.6
(104.0, 
111.1)
33.1
(134.8, 68.7)
41.7
(180.5, 97.0)
2.7
(140.9, 
146.3)
26.1
(165.5, 
113.3)
P value vs PBO 0.992 0.948 0.523 0.554 0.970 0.713
Medial *  
(209.7, 
*!$
*
(200.6, 
*
* #
(207.7, 
* 
*#"
(194.1, 
*##
*! 
(353.3, 
*!!#
*#"#
(379.4, 
*!#
*!  "
(331.8, 
*! 
*#
(372.8, 
*!$
Difference vs PBO 7.4
(51.1, 65.8)
3.8
(57.8, 65.3)
13.2
(45.0, 71.4)
30.5
(120.2, 59.1)
20.1
(72.8, 112.9)
24.0
(114.0, 65.9)
P value vs PBO 0.804 0.904 0.655 0.503 0.670 0.599
Lateral * 
(214.2, 
*$
*  #
(218.5, 
*$
*
(214.8, 
*#
*!$
(255.7, 
*!$
*!""
(336.3, 
*!
*!
(342.1, 
*!"
*!"
(352.0, 
*!!#"
*!"
(332.3, 
*!
Difference vs PBO 6.7
(81.2, 67.9)
1.6
(76.9, 80.0)
44.5
(118.7, 29.8)
10.2
(98.7, 78.3)
17.2
(108.7, 74.3)
0.4
(89.4, 88.5)
P value vs PBO 0.860 0.969 0.239 0.820 0.711 0.992
Exploratory endpoint
JSN, mm
n     58 70 64 68
Medial     0.00 * * * 
Page 79 of 131
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
(0.110, 
0.119)
(0.287, 
*"
(0.218, 
*#
(0.165, 
0.047)
Difference vs PBO 0.19
(0.341, 
*#$
0.12
(0.272, 
0.041)
0.06
(0.218, 
0.090)
P value vs PBO     &'&()* 0.148 0.415
Lateral     * 
(0.310, 
*
0.14
(0.003, 
0.275)
*"
(0.216, 
0.073)
0.04
(0.106, 
0.177)
Difference vs PBO 0.29
(0.089, 0.498)
0.09
(0.123, 
0.295)
0.19
(0.012, 
0.399)
P value vs PBO     &'&&+* 0.418 0.065
Data are least squares means (95% CI).
JSN, joint space narrowing; KL, Kellgren-Lawrence; LOCF, last observation carried forward; OMERACT/OARSI, Outcome Measures 
in Rheumatology Clinical Trials/Osteoarthritis Research Society International; PBO, placebo; Q2W, every 2 weeks; SC, subcutaneous; 
WOMAC, Western Ontario and McMaster Universities Osteoarthritis index; WORMS, Whole-Organ Magnetic Resonance Imaging 
Score.
*PE vs PBO. Continuous variables compared with analysis of covariance with treatment, age, and KL grade as main factors and 
baseline as covariate. Categorical variables compared with Cochran-Mantel-Haenszel test with age group and KL grade as stratification 
factors.
OMERACT/OARSI response defined as either (1) H3 relative and H!3 absolute improvement from baseline in WOMAC pain or 
function or (2) H!3 relative and H3 from baseline in at least 2 of 3 measures (WOMAC pain, WOMAC function, and patient 
global assessment).
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Table 3. Safety Results
Lutikizumab SC Q2W, mg
Placebo 
(n=85) 25 (n=89) 100 (n=85) 200 (n=88)
Any AE 78 (91.8) 78 (87.6) 77 (90.6) 81 (92.0)
Discontinuation of study drug due to 
AE
10 (11.8) 5 (5.6) 5 (5.9) 12 (13.6)
Deaths 0 0 0 0
Serious AE 8 (9.4) 11 (12.4) 8 (9.4) 4 (4.5)
Serious AE occurring in " 
subjects/arm
Infection* 2 (2.4) 2 (2.2) 1 (1.2) 0
Fracture and injury* 4 (4.7) 3 (3.4) 3 (3.5) 1 (1.1)
Malignancy 0 3 (3.4) 1 (1.2) 2 (2.3)
Basal cell carcinoma 0 3 (3.4) 0 0
Invasive ductal breast carcinoma 0 0 0 1 (1.1)
Lung cancer metastatic 0 0 0 1 (1.1)
PSA increased 0 0 1 (1.2) 0
Any infection 39 (45.9) 34 (38.2) 42 (49.4) 49 (55.7)
Serious infection 2 (2.4) 2 (2.2) 1 (1.2) 0
Appendicitis 0 1 (1.1) 0 0
Diverticulitis 1 (1.2) 0 0 0
Peritonitis 0 1 (1.1) 0 0
Pneumonia 0 0 1 (1.2) 0
Urinary tract infection 1 (1.2) 0 0 0
Injection site reaction 13 (15.3) 16 (18.0) 21 (24.7) 29 (33.0),
Neutropenia (grade 2, 3, or 4) 3 (3.5) 18 
(20.5)--.,
26 (30.6), 33 (37.5),
Neutropenia (grade 2; 1000
<1500/mm3)
3 (3.5) 17 
(19.3)--.,
25 (29.4), 28 (31.8),
Neutropenia (grade 3; 500
<1000/mm3)
0 1 (1.1)-- 1 (1.2) 5 (5.7)
Neutropenia (grade 4; <500/mm3) 0 0-- 0 0
Neutropenia leading to 
discontinuation of study drug
0 1 (1.1) 0 6 (6.8),
Lymphopenia (grade 3 or 4/) 1 (1.2) 1 (1.2)-- 1 (1.2) 2 (2.3)
Hypertriglyceridemia (grade 3 or 42) 0 3 (3.4)-- 1 (1.2) 2 (2.3)
AE, adverse event; Q2W, every 2 weeks; PSA, prostatic specific antigen; SC, subcutaneous.
*A patient who reported 2 or more different preferred terms which are in the same system organ 
class was counted only once in the total.
The PSA was described by the site investigat  biopsy was 
performed a vated PSA is listed under 
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malignancies in this table, but the total number of malignancies is reported as 5, rather than 6, 
elsewhere in the article.
3Grade 3, 200<500 /mm3; grade 4, <200/mm3.
4Grade 3, >5001000 mg/dL; grade 4, >1000 mg/dL.
55Data missing for 1 patient.
6P<0.05 for comparison with placebo, Fisher exact test.
Grades for laboratory abnormalities were defined by Common Terminology Criteria for Adverse 
Events, version 4.03.(40)
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Subjects
Key exclusion criteria included significant trauma or surgery to the index knee within the last 
year or arthroscopy of the index knee within 6 months of the initial screening visit; severe knee 
malalignment, either in varus or in valgus angulation in the index knee; previous 
exposure to antiIL-1 treatment; intra-articular corticosteroids within 3 months or via another 
route within 1 month before screening; and use of any investigational or immunosuppressive 
therapy within 1 month or 5 half-lives, whichever was longer, before the first dose of study drug. 
Subject disposition was calculated for the intent-to-treat population, comprising all randomized 
patients.
Efficacy
Secondary endpoints included 3 types of pain intensity measures using 11-point numeric rating 
scales patient-rated pain from 0 ] to 10 possible in which 
subjects were asked about the average pain intensity during the past week (7-day recall period), 
worst pain during activity over the past 24 hours (activity pain), and pain intensity before and 
after a 40-meter walk (performance pain) at weeks 16, 26, and 52; Western Ontario and 
McMaster Universities Osteoarthritis (WOMAC) physical function scores (0170 scale, NRS-11 
subscales)(1) at weeks 16, 26, and 52; patient global assessment of arthritis at weeks 16, 26, and 
52; Whole-Organ Magnetic Resonance Imaging Score (WORMS) bone marrow lesion(s)(2) at 
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weeks 26 and 52; and magnetic resonance imaging (MRI) cartilage volume and thickness at 
weeks 26 and 52.
Patients meeting criteria for B-mode synovial hypertrophy or power Doppler were selected for 
further screening. For selection and quality assurance, sonographers were asked to submit test 
scans for B-mode and power Doppler images. B-mode frequency started at 12 MhZ and could be 
reduced for penetration. Gain was set at approximately 50%. Using the index fingertip, Doppler 
settings were optimized for respective equipment to show vascularity in at least one third of the 
finger pulp. The pulse repetition frequency was set in a range between 400 to 600 Hz, with 
Doppler box to cover recess and superficial tissue, and gain just above noise. Doppler frequency 
was adjusted for the highest sensitivity. The knee was placed in flexion, and the B-mode 
synovial hypertrophy was measured at the suprapatellar recess and parapatellar recesses.(3, 4) 
The following cutoffs were used to select patients for further screening: distension of midline 
suprapatellar recess I(  mm, medial parapatellar recess I( ! mm, lateral parapatellar recess 
I( ( mm. Since the suprapatellar recess is insensitive to Doppler inspection for synovitis, the 
medial and lateral parapatellar recesses were chosen. Scans were acquired using a gel standoff 
assuring minimal pressure on the recess. Semiquantitative scoring was used: grade 0, no signal; 
grade 1, J( single vessels; grade 2, >3 single or confluent blood vessels in less than half the 
synovial area; grade 3, vessel signals in more than half the synovial area. In addition to meeting 
the B-mode criteria for inclusion, a power Doppler score of I8 at the parapatellar recesses was 
one of the independent cutoffs for further screening.
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Posteroanterior weight-bearing radiographs of the target knee were acquired at screening and at 
week 52, using the fixed-flexion te udal beam angulation using a positioning 
frame and calibration phantom. Knee joint space width (JSW) measurements were made using a 
computer-assisted algorithm (KneeAnalyzer, Optasia Medical, Manchester, United Kingdom) 
that identified the contours of the femoral condyles and tibia plateau. A single radiologist (O.V.) 
reviewed computer-generated contours and adjusted them, if necessary. Software then computed 
the minimum JSW in the weight-bearing region of the medial and lateral compartments. The 
method was highly reproducible, with intraclass correlation coefficient (ICC) of 0.98 and root 
mean square coefficient of variation of 0.18 mm. 
Magnetic
Pulse sequences included sagittal 2-dimensional (2D) proton-density weighted (PD-w) fast spin 
echo (FSE) with spectral fat saturation (FS), axial 2D in/out-of-phase T1-weighted gradient echo 
(GRE), sagittal 3-dimensional T1-weighted GRE with FS or selective water excitation, coronal 
2D PD-w FSE with FS, and axial 2D PD-w FSE with FS. The same scanners were used at 
baseline and follow-up.
All WORMS assessments were performed with multiple time points viewed simultaneously by a 
single central radiologist who was blinded to time point order. WORMS inter-reader ICCs have 
previously been shown to range from 0.61 to 0.99, depending on the feature.(2)
Page 88 of 131
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
4
The extent of synovitis was assessed by measuring its thickness in mm in 4 regions of interest: 
the medial and lateral recess and the medial and lateral border of the suprapatellar bursa.(5) The 
intra-reader and inter-reader correlation coefficients were r=0.91 and r=0.82, respectively 
(P<0.0001).
The synovial fluid volume was assessed using a fully automated system as described (6) with a 
correlation coefficient with manual quantification of r=0.98 (P<0.0001) and direct aspiration 
r=0.88 (P=0.0008).
Semi-automated cartilage volume/thickness was measured as previously described.(7-9). The 
change in knee cartilage volume/thickness was obtained by subtracting the initial (baseline) 
volume/thickness from follow-up volume/thickness and calculated compared with initial 
(baseline) volume/thickness in percentage values. Between-reader agreement of measurement 
had ICCs ranging from 0.958 to 0.997 (P<0.0001) for global knee cartilage. Test-retest reliability 
of within-reader measurements had Pearson correlation coefficients ranging from 0.978 to 0.999 
(P<0.0001).(8) Automated cartilage volume/thickness was assessed as described and validated 
(10, 11) with a test-retest measure he global knee (10). 
Dynamic Contrast Enhanced Magnetic Resonanc
The following parameters were defined for quantitative analysis of the dynamic changes in 
synovial fluid using dynamic contrast enhanced MRI (DCE-MRI):
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 Initial rate of enhancement (IRE): slope of the enhancement versus time curve from 
initial onset of enhancement to the time of plateau or until the end of acquisition if a 
plateau pattern is not observed. IRE is computed for each voxel in the image stack and 
the mean IRE is calculated for all voxels within the measurement volume of interest
 Maximum enhancement (ME): maximum increase in enhancement from precontrast 
images to the time point of maximum enhancement. ME is computed for each voxel in 
the image stack and the mean ME is calculated for all voxels within the measurement 
volume of interest
 Enhanci ume of tissue (in mL) demonstrating plateau or washout 
charac l to the product of the number of enhancing voxels within 
the volume of interest, plateau, or washout) and the volume of an individual voxel, 
determined by the area of a voxel in-plane and the slice separation
o ber of pixels with persistent 
uptake/classified pixels
o eau uptake: L h plateau 
uptake/classified pixels
o s with washout 
uptake/classified pixels
 IAUGC60: initial area under the gadolinium curve at time 60 seconds
 DEMRIQ ME Score (DEMRIQ
  IR L
 Ktrans: rate contrast for the diffusion of contrast between locally defined blood and tissue 
regions of interest
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 VE: proportion (01) of extravascular extracellular space present in the tissue region of 
interest
The analysis of the DCE MRI scans used 2 independent readers and a third reader for 
adjudication of discrepancies. For each single measurement, if there was only 1 raw read, it was 
used as the measurement value; if there were 2 reads, they were averaged; if there were 2 raw 
reads and 1 adjudicator read, the adjudicator read was averaged with the closest raw read.
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l y Entry Based on Evidence of Knee Synovitis
Lutikizumab SC Q2W, mg
 n Placebo 25 100 200 Total
Ultrasound or MRI 84 89 84 87 3 347
Ultrasound 53 56 55 63 2 229
Without MRI 48 56 54 60 2 220
With positive MRI 3 0 1 2 0 6
With negative MRI 2 0 0 1 0 3
MRI 31 33 29 24 1 118
None 0 0 1* 0 0 1*
Missing 1 0 1* 0 0 2*
MRI, magnetic resonance imaging; Q2W, every 2 weeks; SC, subcutaneous.
*Inadvertently enrolled despite the lack of evidence of synovitis; 1 of these 3 subjects had 
synovitis at baseline based on the Whole-Organ Magnetic Resonance Imaging Score assessment.
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lemental Table 2. Changes F y Endpoints in Subjects With Positive WORMS Synovitis/Effusion at 
Baseline
Signs and Symptoms Endpoints (LOCF Data)
Week 16 Week 52
Lutikizumab SC Q2W, mg Lutikizumab SC Q2W, mg
:;<=>?;@ ABCDD FGHDIJ PBO (n=72) 25 (n=78) 100 (n=65) 200 (n=79) PBO (n=72) 25 (n=78) 100 (n=65) 200 (n=79)
Co-primary endpoint
WOMAC pain
(050; higher scores 
indicate worse 
condition)
\# 
.\!  
\* 7M6
\! (
.\8 *# 
\# !#6
\ 7
.\ 7 
\M 86
\ M
.\  
\M 6
\M 
.\ ! 
\ *76
\8 
.\ # 
\M 86
\ M
.\ *# 
\M 876
\8 *
.\ ## 
\! !76
Difference vs PBO \8 8
.\* ( 1.00)
\( 
.\ M# \! 886
\( #
.\ M7 \! *6
\( !
.\  0.51)
\8 #
.\ *! 0.81)
\( 
.\ # 0.07)
P value vs PBO 0.176 0.037* 0.021* 0.094 0.127 0.055
Secondary endpoint
WOMAC function
(0170; higher scores 
indicate worse 
condition)
\8M 
.\(  
\8 #86
\( 
.\(# *( 
\8 (6
\( (
.\( MM 
\8# *(6
\(8 
.\(M  
\8* *86
\( !
.\(M 8 
\88 (6
\(M 8
.\7 *M 
\(! #76
\(M !
.\# ( 
\8M M6
\! 
(48.65, 
\(8 !*6
Difference vs PBO \8 ( .\8  
7.84)
\7  .\7 7 
3.52)
\(  .\( *( 
6.68)
\# 8 .\8! # 
3.70)
\# ! .\8! *7 
4.50)
\M  .\8 87 
\8 **6
P value vs PBO 0.656 0.189 0.506 0.176 0.208 0.123
Exploratory endpoint
OMERACT/OARSI 
response, %
59.7 (48.4, 
71.1)
68.8 (58.5, 
79.2)
71.9 (60.9, 
82.9)
65.4 (54.8, 
75.9)
68.1 (57.3, 
78.8)
74.0 (64.2, 
83.8)
73.4 (62.6, 
84.3)
73.4 (63.7, 
83.2)
Difference vs PBO 9.1 .\ 8 
24.5)
12.2 .\(  
28.0)
5.7 .\M # 
21.1)
6.0 .\#  
20.5)
5.4 .\M M 
20.6)
5.4 .\M 8 
19.9)
P value vs PBO 0.253 0.123 0.457 0.448 0.577 0.484
Structural Endpoints (Observed Data)
Week 26 Week 52
Lutikizumab SC Q2W, mg Lutikizumab SC Q2W, mg
Endpoint PBO 25 100 200 PBO 25 100 200
Co-primary endpoint
Synovial membrane 
thickness, mm
\! ! .\! 8 
0.01)
0.03 .\! !( 
0.09)
\! !7 .\! ( 
\! !!(6
\! !! .\! ! 
0.06)
\! !# .\! * 
\! !6
\! !( .\! !M 
0.03)
\! !* .\! 8 
0.02)
\! !8 .\! !M 
0.04)
n 49 56 49 59 44 52 46 50
Difference vs PBO 0.08
.\! ! 0.17)
\! !
.\! ! 0.08)
0.05
(0.03, 0.14)
0.05
.\! ! 0.14)
0.03
.\! !7 0.12)
0.05
.\! ! 0.15)
P value vs PBO 0.064 0.819 0.219 0.291 0.554 0.247
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Synovial fluid volume, 
mL
\! ! .\8 MM 
2.96)
0.07 .\8 *# 
2.73)
\! 7* .\( ! 
2.10)
\8 * .\ #8 
0.52)
\8 (# .\* M 
1.18)
0.88 .\8 (# 
4.13)
\! * .\( M8 
3.02)
\8 (( .\*  
0.98)
n 49 62 53 61 46 55 48 53
Difference vs PBO 0.09 .\( #7 
4.04)
\! 7 .\ # 
3.37)
\8 ( .\  
1.84)
3.26 .\ *8 
8.04)
1.93 .\( ! 
6.90)
0.05 .\ 7# 
4.88)
P value vs PBO 0.966 0.724 0.291 0.181 0.444 0.984
WORMS 
semiquantitative 
synovitis/effusion 
volume
0.09 .\! !* 
0.23)
\! !8 .\!  
0.11)
\! !# .\! 8( 
0.06)
\! 8 .\! 8* 
0.02)
\! ! .\! 8! 
0.09)
\! !7 .\! 8 
0.07)
\! !# .\! 8( 
0.07)
\! ! .\! 8! 
0.07)
n 58 67 57 68 51 58 51 61
Difference vs PBO \!  .\! ( 
0.08)
\! 7 .\! (7 
0.03)
\! 8! .\! ! 
\! !6
\! !8 .\! 88 
0.19)
\! !8 .\! 8( 
0.18)
\! ! .\! 8! 
0.19)
P value vs PBO 0.255 0.098 0.039 0.880 0.813 0.955
Data are least squares means (95% CI).
KL, Kellgren-Lawrence; LOCF, last observation carried forward; OMERACT/OARSI, Outcome Measures in Rheumatology Clinical 
Trials/Osteoarthritis Research Society International; PBO, placebo; Q2W, every 2 weeks; SC, subcutaneous; WOMAC, Western 
Ontario and McMaster Universities Osteoarthritis index; WORMS, Whole-Organ Magnetic Resonance Imaging Score.
*PJ! !* vs PBO. Continuous variables compared with analysis of covariance with treatment, age, and KL grade as main factors and 
baseline as covariate. Categorical variables compared with Cochran-Mantel-Haenszel test with age group and KL grade as stratification 
factors.
OMERACT/OARSI response defined as either (1) I*!E relative and I8!E absolute improvement from baseline in WOMAC pain or 
function or (2) I8!E relative and I!E from baseline in at least 2 of 3 measures (WOMAC pain, WOMAC function, and patient 
global assessment).
Page 95 of 131
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
11
lemental Table 3. Change From Baseline in DCE-MRI Parameters in Synovial Membrane at Week 26
Lutikizumab SC Q2W, mg
Parameter, LS Mean (%) Change Placebo (n=7) 25 (n=10) 100 (n=10) 200 (n=12)
IRE* 0.002 (25.0) 0.002 (5.5) 0.002 (46.3K) 0.003 (7.9)
ME* 0.040 (3.2) 0.030 (2.4) 0.119 (9.5) 0.096 (3.3)
0.337 (67.7) 0.711 (273.9) 7.001 (28.6) 6.950 (15.3)
Persistent uptake* 0.049 (7.1) 0.129 (113.0) 0.136 (27.1) 0.023 (59.2)
Plateau uptake* 0.363 (87.3) 0.672 (379.2) 7.254 (37.6) 5.091 (18.1)
Washout uptake* 0.872 (106.3) 0.214 (244.5) 0.240 (16.4) 1.519L (37.1)
IAUGC60, m  0.519 (20.4) 0.191 (0.8) 1.241 (61.6) 1.134 (7.2)
DEMRIQ ME score, mL* 0.140 (67.2) 4.025 (318.6) 20.505 (35.1) 18.734 (34.0)
DEMRIQ IRE score, mL* 0.134 (35.9) 0.091 (342.9) 0.188 (56.1) 0.242 (49.8)
Ktrans, min\] 0.058 (51.5) 0.003 (25.5) 0.052 (329.9) 0.045 (319.1)
VE 0.391 (23.6) 0.169 (20.9) 0.515 (5.5) 0.545 (38.3)
DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; DEMRIQ, DCE-MRI quantificati ume; 
IAUGC60, initial area under the gadolinium concentration-time curve over 60 s; IRE, initial rate of enhancement; KL, Kellgren-
Lawrence; Ktrans, volume transfer coefficient; LS, least squares; ME, maximal enhancement; Q2W, every 2 weeks; SC, subcutaneous; 
VE, fractional extracellular extravascular space.
*n=5, 8, 10, and 10 and n= 5, 6, 10, and 10 for placebo and lutikizumab 25 mg, 100 mg, and 200 mg, respectively.
P=0.016 and LP=0.043 vs placebo from analysis of covariance with treatment, age, and KL grade as main factors and baseline as 
covariate.
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lemental Table 4. Concomitant Medication Use During the Treatment Period*
Lutikizumab SC Q2W, mg
n (%) Placebo (n=85) 25 (n=89) 100 (n=85) 200 (n=88)
Any concomitant 
medication, n (%)
84 (98.8) 87 (97.8) 82 (96.5) 87 (98.9)
Ibuprofen 37 (43.5) 26 (29.2) 29 (34.1) 39 (44.3)
Acetaminophen 75 (88.2) 66 (74.2) 68 (80.0) 78 (88.6)
Q2W, every 2 weeks; SC, subcutaneous.
*First study drug dose through 14 days after the final study drug dose.
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lemental Table 5. Proportion of Subjects With Decreases From Baseline in ; :> 2 
Weeks After Initiating Treatment With Placebo or Lutikizumab
Treatment Subjects, n/N (%)
Placebo 4/40 (10.0)
Lutikizumab 25 mg SC Q2W 17/37 (45.9)
Lutikizumab 100 mg SC Q2W 10/34 (29.4)
Lutikizumab 200 mg SC Q2W 11/40 (27.5)
%&'aP	
'a Q2W, every 2 weeks; SC, subcutaneous.
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lemental Figure 1. Study design. JSN, joint space narrowing; MRI, magnetic resonance 
imaging; Q2W, every 2 weeks; SC, subcutaneous; WOMAC, Western Ontario and McMaster 
Universities Osteoarthritis index; WORMS, Whole-Organ Magnetic Resonance Imaging Score.
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lemental Figure 2. LS mean percentage change from baseline over time for WOMAC pain 
(A) and WOMAC function . LS, least squares; Q2W, every 2 weeks; WOMAC, Western 
Ontario and McMaster Universities Osteoarthritis index. *PJ! !* vs placebo; PJ! ! vs 
placebo.
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l LS mean change from baseline over time for WOMAC pain using MI. 
LS, least squares; MI, multiple imputation; Q2W, every 2 weeks; WOMAC, Western Ontario 
and McMaster Universities Osteoarthritis index. *PJ! !* vs placebo; PJ! ! vs placebo.
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l LS mean change from baseline over time for WOMAC pain in subjects 
with positive WORMS synovitis/effusion at baseline. LS, least squares; Q2W, every 2 weeks; 
WOMAC, Western Ontario and McMaster Universities Osteoarthritis index; WORMS, Whole-
Organ Magnetic Resonance Imaging Score. *PJ! !* vs placebo; PJ! ! vs placebo.
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lemental Figure 5. Mean (SD) trough serum concentrations of lutikizumab over time for 
all subjects (A) and separated by presence of ADAs . ADA, anti-drug antibody; Q2W, every 
2 weeks.
1
10
100
Week
L
u
ti
k
iz
u
m
a
b
 T
ro
u
g
h
 C
o
n
c
e
n
tr
a
ti
o
n
,
 g
/m
L Lutikizumab 25 mg Q2W
Lutikizumab 100 mg Q2W
Lutikizumab 200 mg Q2W
0 4 8 12 16 20 24 28 32 36 40 44 48 52
A
0 4 8 12 16 20 24 28 32 36 40 44 48 52
1
10
100
Week
L
u
ti
k
iz
u
m
a
b
 T
ro
u
g
h
 C
o
n
c
e
n
tr
a
ti
o
n
,
g
/m
L Lutikizumab 25 mg Q2W ADA+ Lutikizumab 25 mg Q2W ADA-
Lutikizumab 100 mg Q2W ADA+ Lutikizumab 100 mg Q2W ADA-
Lutikizumab 200 mg Q2W ADA+ Lutikizumab 200 mg Q2W ADA-
B
 
Page 103 of 131
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
19
l Median absolute neutrophil counts for placebo and lutikizumab serum 
concentration quartiles at week 52 (observed cases).
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lemental Figure 7. Change From Day 1 in Serum ; :@ Levels at 2 Weeks After 
Initiating Treatment With Placebo or Lutikizumab. %&'bP	
'b Q2W=every 2 
weeks.
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lemental Figure 8. Median change from baseline over time for the biomarkers C1M (A), 
C3M , and CRPM (C), median percentage change from baseline over time in IL-6 ( , and 
mean change from baseline over time in alkaline phosphatase (E). C1M, metalloproteinase-
degraded collagen type I; C3M, metalloproteinase-degraded collagen type III; CRPM, matrix 
metalloproteinase-generated fragment of C-reactive protein; IL-6, interleukin-6; Q2W, every 2 
weeks.
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lemental Figure 8 continued.
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Subjects
Key exclusion criteria included significant trauma or surgery to the index knee within the last 
year or arthroscopy of the index knee within 6 months of the initial screening visit; severe knee 
malalignment, either in varus or in valgus angulation in the index knee; previous 
exposure to antiIL-1 treatment; intra-articular corticosteroids within 3 months or via another 
route within 1 month before screening; and use of any investigational or immunosuppressive 
therapy within 1 month or 5 half-lives, whichever was longer, before the first dose of study drug. 
Subject disposition was calculated for the intent-to-treat population, comprising all randomized 
patients.
Efficacy
Secondary endpoints included 3 types of pain intensity measures using 11-point numeric rating 
scales patient-rated pain from 0 ] to 10 possible in which 
subjects were asked about the average pain intensity during the past week (7-day recall period), 
worst pain during activity over the past 24 hours (activity pain), and pain intensity before and 
after a 40-meter walk (performance pain) at weeks 16, 26, and 52; Western Ontario and 
McMaster Universities Osteoarthritis (WOMAC) physical function scores (0170 scale, NRS-11 
subscales)(1) at weeks 16, 26, and 52; patient global assessment of arthritis at weeks 16, 26, and 
52; Whole-Organ Magnetic Resonance Imaging Score (WORMS) bone marrow lesion(s)(2) at 
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weeks 26 and 52; and magnetic resonance imaging (MRI) cartilage volume and thickness at 
weeks 26 and 52.
Patients meeting criteria for B-mode synovial hypertrophy or power Doppler were selected for 
further screening. For selection and quality assurance, sonographers were asked to submit test 
scans for B-mode and power Doppler images. B-mode frequency started at 12 MhZ and could be 
reduced for penetration. Gain was set at approximately 50%. Using the index fingertip, Doppler 
settings were optimized for respective equipment to show vascularity in at least one third of the 
finger pulp. The pulse repetition frequency was set in a range between 400 to 600 Hz, with 
Doppler box to cover recess and superficial tissue, and gain just above noise. Doppler frequency 
was adjusted for the highest sensitivity. The knee was placed in flexion, and the B-mode 
synovial hypertrophy was measured at the suprapatellar recess and parapatellar recesses.(3, 4) 
The following cutoffs were used to select patients for further screening: distension of midline 
suprapatellar recess I(  mm, medial parapatellar recess I( ! mm, lateral parapatellar recess 
I( ( mm. Since the suprapatellar recess is insensitive to Doppler inspection for synovitis, the 
medial and lateral parapatellar recesses were chosen. Scans were acquired using a gel standoff 
assuring minimal pressure on the recess. Semiquantitative scoring was used: grade 0, no signal; 
grade 1, J( single vessels; grade 2, >3 single or confluent blood vessels in less than half the 
synovial area; grade 3, vessel signals in more than half the synovial area. In addition to meeting 
the B-mode criteria for inclusion, a power Doppler score of I8 at the parapatellar recesses was 
one of the independent cutoffs for further screening.
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Posteroanterior weight-bearing radiographs of the target knee were acquired at screening and at 
week 52, using the fixed-flexion te udal beam angulation using a positioning 
frame and calibration phantom. Knee joint space width (JSW) measurements were made using a 
computer-assisted algorithm (KneeAnalyzer, Optasia Medical, Manchester, United Kingdom) 
that identified the contours of the femoral condyles and tibia plateau. A single radiologist (O.V.) 
reviewed computer-generated contours and adjusted them, if necessary. Software then computed 
the minimum JSW in the weight-bearing region of the medial and lateral compartments. The 
method was highly reproducible, with intraclass correlation coefficient (ICC) of 0.98 and root 
mean square coefficient of variation of 0.18 mm. 
Magnetic
Pulse sequences included sagittal 2-dimensional (2D) proton-density weighted (PD-w) fast spin 
echo (FSE) with spectral fat saturation (FS), axial 2D in/out-of-phase T1-weighted gradient echo 
(GRE), sagittal 3-dimensional T1-weighted GRE with FS or selective water excitation, coronal 
2D PD-w FSE with FS, and axial 2D PD-w FSE with FS. The same scanners were used at 
baseline and follow-up.
All WORMS assessments were performed with multiple time points viewed simultaneously by a 
single central radiologist who was blinded to time point order. WORMS inter-reader ICCs have 
previously been shown to range from 0.61 to 0.99, depending on the feature.(2)
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The extent of synovitis was assessed by measuring its thickness in mm in 4 regions of interest: 
the medial and lateral recess and the medial and lateral border of the suprapatellar bursa.(5) The 
intra-reader and inter-reader correlation coefficients were r=0.91 and r=0.82, respectively 
(P<0.0001).
The synovial fluid volume was assessed using a fully automated system as described (6) with a 
correlation coefficient with manual quantification of r=0.98 (P<0.0001) and direct aspiration 
r=0.88 (P=0.0008).
Semi-automated cartilage volume/thickness was measured as previously described.(7-9). The 
change in knee cartilage volume/thickness was obtained by subtracting the initial (baseline) 
volume/thickness from follow-up volume/thickness and calculated compared with initial 
(baseline) volume/thickness in percentage values. Between-reader agreement of measurement 
had ICCs ranging from 0.958 to 0.997 (P<0.0001) for global knee cartilage. Test-retest reliability 
of within-reader measurements had Pearson correlation coefficients ranging from 0.978 to 0.999 
(P<0.0001).(8) Automated cartilage volume/thickness was assessed as described and validated 
(10, 11) with a test-retest measure he global knee (10). 
Dynamic Contrast Enhanced Magnetic Resonanc
The following parameters were defined for quantitative analysis of the dynamic changes in 
synovial fluid using dynamic contrast enhanced MRI (DCE-MRI):
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 Initial rate of enhancement (IRE): slope of the enhancement versus time curve from 
initial onset of enhancement to the time of plateau or until the end of acquisition if a 
plateau pattern is not observed. IRE is computed for each voxel in the image stack and 
the mean IRE is calculated for all voxels within the measurement volume of interest
 Maximum enhancement (ME): maximum increase in enhancement from precontrast 
images to the time point of maximum enhancement. ME is computed for each voxel in 
the image stack and the mean ME is calculated for all voxels within the measurement 
volume of interest
 Enhanci ume of tissue (in mL) demonstrating plateau or washout 
charac l to the product of the number of enhancing voxels within 
the volume of interest, plateau, or washout) and the volume of an individual voxel, 
determined by the area of a voxel in-plane and the slice separation
o ber of pixels with persistent 
uptake/classified pixels
o eau uptake: L h plateau 
uptake/classified pixels
o s with washout 
uptake/classified pixels
 IAUGC60: initial area under the gadolinium curve at time 60 seconds
 DEMRIQ ME Score (DEMRIQ
  IR L
 Ktrans: rate contrast for the diffusion of contrast between locally defined blood and tissue 
regions of interest
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 VE: proportion (01) of extravascular extracellular space present in the tissue region of 
interest
The analysis of the DCE MRI scans used 2 independent readers and a third reader for 
adjudication of discrepancies. For each single measurement, if there was only 1 raw read, it was 
used as the measurement value; if there were 2 reads, they were averaged; if there were 2 raw 
reads and 1 adjudicator read, the adjudicator read was averaged with the closest raw read.
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l y Entry Based on Evidence of Knee Synovitis
Lutikizumab SC Q2W, mg
Evidence Source, n Placebo 25 100 200 Untreated Total
Ultrasound or MRI 84 89 84 87 3 347
Ultrasound 53 56 55 63 2 229
Without MRI 48 56 54 60 2 220
With positive MRI 3 0 1 2 0 6
With negative MRI 2 0 0 1 0 3
MRI 31 33 29 24 1 118
None 0 0 1* 0 0 1*
Missing 1 0 1* 0 0 2*
MRI, magnetic resonance imaging; Q2W, every 2 weeks; SC, subcutaneous.
*Inadvertently enrolled despite the lack of evidence of synovitis; 1 of these 3 subjects had 
synovitis at baseline based on the Whole-Organ Magnetic Resonance Imaging Score assessment.
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lemental Table 2. Changes From Baseline in Efficacy Endpoints in Subjects With Positive WORMS Synovitis/Effusion at 
Baseline
Signs and Symptoms Endpoints (LOCF Data)
Week 16 Week 52
Lutikizumab SC Q2W, mg Lutikizumab SC Q2W, mg
Endpoint (Full Scale) PBO (n=72) 25 (n=78) 100 (n=65) 200 (n=79) PBO (n=72) 25 (n=78) 100 (n=65) 200 (n=79)
Co-primary endpoint
WOMAC pain
(050; higher scores 
indicate worse 
condition)
\# 
.\!  
\* 7M6
\! (
.\8 *# 
\# !#6
\ 7
.\ 7 
\M 86
\ M
.\  
\M 6
\M 
.\ ! 
\ *76
\8 
.\ # 
\M 86
\ M
.\ *# 
\M 876
\8 *
.\ ## 
\! !76
Difference vs PBO \8 8
.\* ( 1.00)
\( 
.\ M# \! 886
\( #
.\ M7 \! *6
\( !
.\  0.51)
\8 #
.\ *! 0.81)
\( 
.\ # 0.07)
P value vs PBO 0.176 0.037* 0.021* 0.094 0.127 0.055
Secondary endpoint
WOMAC function
(0170; higher scores 
indicate worse 
condition)
\8M 
.\(  
\8 #86
\( 
.\(# *( 
\8 (6
\( (
.\( MM 
\8# *(6
\(8 
.\(M  
\8* *86
\( !
.\(M 8 
\88 (6
\(M 8
.\7 *M 
\(! #76
\(M !
.\# ( 
\8M M6
\! 
(48.65, 
\(8 !*6
Difference vs PBO \8 ( .\8  
7.84)
\7  .\7 7 
3.52)
\(  .\( *( 
6.68)
\# 8 .\8! # 
3.70)
\# ! .\8! *7 
4.50)
\M  .\8 87 
\8 **6
P value vs PBO 0.656 0.189 0.506 0.176 0.208 0.123
Exploratory endpoint
OMERACT/OARSI 
response, %
59.7 (48.4, 
71.1)
68.8 (58.5, 
79.2)
71.9 (60.9, 
82.9)
65.4 (54.8, 
75.9)
68.1 (57.3, 
78.8)
74.0 (64.2, 
83.8)
73.4 (62.6, 
84.3)
73.4 (63.7, 
83.2)
Difference vs PBO 9.1 .\ 8 
24.5)
12.2 .\(  
28.0)
5.7 .\M # 
21.1)
6.0 .\#  
20.5)
5.4 .\M M 
20.6)
5.4 .\M 8 
19.9)
P value vs PBO 0.253 0.123 0.457 0.448 0.577 0.484
Structural Endpoints (Observed Data)
Week 26 Week 52
Lutikizumab SC Q2W, mg Lutikizumab SC Q2W, mg
Endpoint PBO 25 100 200 PBO 25 100 200
Co-primary endpoint
Synovial membrane 
thickness, mm
\! ! .\! 8 
0.01)
0.03 .\! !( 
0.09)
\! !7 .\! ( 
\! !!(6
\! !! .\! ! 
0.06)
\! !# .\! * 
\! !6
\! !( .\! !M 
0.03)
\! !* .\! 8 
0.02)
\! !8 .\! !M 
0.04)
n 49 56 49 59 44 52 46 50
Difference vs PBO 0.08
.\! ! 0.17)
\! !
.\! ! 0.08)
0.05
(0.03, 0.14)
0.05
.\! ! 0.14)
0.03
.\! !7 0.12)
0.05
.\! ! 0.15)
P value vs PBO 0.064 0.819 0.219 0.291 0.554 0.247
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Synovial fluid volume, 
mL
\! ! .\8 MM 
2.96)
0.07 .\8 *# 
2.73)
\! 7* .\( ! 
2.10)
\8 * .\ #8 
0.52)
\8 (# .\* M 
1.18)
0.88 .\8 (# 
4.13)
\! * .\( M8 
3.02)
\8 (( .\*  
0.98)
n 49 62 53 61 46 55 48 53
Difference vs PBO 0.09 .\( #7 
4.04)
\! 7 .\ # 
3.37)
\8 ( .\  
1.84)
3.26 .\ *8 
8.04)
1.93 .\( ! 
6.90)
0.05 .\ 7# 
4.88)
P value vs PBO 0.966 0.724 0.291 0.181 0.444 0.984
WORMS 
semiquantitative 
synovitis/effusion 
volume
0.09 .\! !* 
0.23)
\! !8 .\!  
0.11)
\! !# .\! 8( 
0.06)
\! 8 .\! 8* 
0.02)
\! ! .\! 8! 
0.09)
\! !7 .\! 8 
0.07)
\! !# .\! 8( 
0.07)
\! ! .\! 8! 
0.07)
n 58 67 57 68 51 58 51 61
Difference vs PBO \!  .\! ( 
0.08)
\! 7 .\! (7 
0.03)
\! 8! .\! ! 
\! !6
\! !8 .\! 88 
0.19)
\! !8 .\! 8( 
0.18)
\! ! .\! 8! 
0.19)
P value vs PBO 0.255 0.098 0.039 0.880 0.813 0.955
Data are least squares means (95% CI).
KL, Kellgren-Lawrence; LOCF, last observation carried forward; OMERACT/OARSI, Outcome Measures in Rheumatology Clinical 
Trials/Osteoarthritis Research Society International; PBO, placebo; Q2W, every 2 weeks; SC, subcutaneous; WOMAC, Western 
Ontario and McMaster Universities Osteoarthritis index; WORMS, Whole-Organ Magnetic Resonance Imaging Score.
*PJ! !* vs PBO. Continuous variables compared with analysis of covariance with treatment, age, and KL grade as main factors and 
baseline as covariate. Categorical variables compared with Cochran-Mantel-Haenszel test with age group and KL grade as stratification 
factors.
OMERACT/OARSI response defined as either (1) I*!E relative and I8!E absolute improvement from baseline in WOMAC pain or 
function or (2) I8!E relative and I!E from baseline in at least 2 of 3 measures (WOMAC pain, WOMAC function, and patient 
global assessment).
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lemental Table n DCE-MRI Parameters in Synovial Membrane at Week 26
Lutikizumab SC Q2W, mg
Parameter, LS Mean (%) Change Placebo (n=7) 25 (n=10) 100 (n=10) 200 (n=12)
IRE* 0.002 (25.0) 0.002 (5.5) 0.002 (46.3M) 0.003 (7.9)
ME* 0.040 (3.2) 0.030 (2.4) 0.119 (9.5) 0.096 (3.3)
0.337 (67.7) 0.711 (273.9) 7.001 (28.6) 6.950 (15.3)
Persistent uptake* 0.049 (7.1) 0.129 (113.0) 0.136 (27.1) 0.023 (59.2)
Plateau uptake* 0.363 (87.3) 0.672 (379.2) 7.254 (37.6) 5.091 (18.1)
Washout uptake* 0.872 (106.3) 0.214 (244.5) 0.240 (16.4) 1.519N (37.1)
IAUGC60, m  0.519 (20.4) 0.191 (0.8) 1.241 (61.6) 1.134 (7.2)
DEMRIQ ME score, mL* 0.140 (67.2) 4.025 (318.6) 20.505 (35.1) 18.734 (34.0)
DEMRIQ IRE score, mL* 0.134 (35.9) 0.091 (342.9) 0.188 (56.1) 0.242 (49.8)
Ktrans, min\] 0.058 (51.5) 0.003 (25.5) 0.052 (329.9) 0.045 (319.1)
VE 0.391 (23.6) 0.169 (20.9) 0.515 (5.5) 0.545 (38.3)
DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; DEMRIQ, DCE-MRI quantificati ume; 
IAUGC60, initial area under the gadolinium concentration-time curve over 60 s; IRE, initial rate of enhancement; KL, Kellgren-
Lawrence; Ktrans, volume transfer coefficient; LS, least squares; ME, maximal enhancement; Q2W, every 2 weeks; SC, subcutaneous; 
VE, fractional extracellular extravascular space.
*n=5, 8, 10, and 10 and n= 5, 6, 10, and 10 for placebo and lutikizumab 25 mg, 100 mg, and 200 mg, respectively.
P=0.016 and NP=0.043 vs placebo from analysis of covariance with treatment, age, and KL grade as main factors and baseline as 
covariate.
Page 119 of 131
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
12
lemental Table 43. Concomitant Medication Use During the Treatment Period*
Lutikizumab SC Q2W, mg
n (%) Placebo (n=85) 25 (n=89) 100 (n=85) 200 (n=88)
Any concomitant 
medication, n (%)
84 (98.8) 87 (97.8) 82 (96.5) 87 (98.9)
Ibuprofen 37 (43.5) 26 (29.2) 29 (34.1) 39 (44.3)
Acetaminophen 75 (88.2) 66 (74.2) 68 (80.0) 78 (88.6)
Q2W, every 2 weeks; SC, subcutaneous.
*First study drug dose through 14 days after the final study drug dose.
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lemental Table . Proportion of Subjects With Decreases From Baseline in ; :> 2 
Weeks After Initiating Treatment With Placebo or Lutikizumab
Treatment Subjects, n/N (%)
Placebo 4/40 (10.0)
Lutikizumab 25 mg SC Q2W 17/37 (45.9)
Lutikizumab 100 mg SC Q2W 10/34 (29.4)
Lutikizumab 200 mg SC Q2W 11/40 (27.5)
%&'aP	
'a Q2W, every 2 weeks; SC, subcutaneous.
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lemental Table 5. ORs for Factors Associated With the Development of Neutropenia 
During Lutikizumab Treatment Based on a Multiple Logistic Regression Model
Variable OR 95% CI P Value
Treatment group <0.0001
Lutikizumab 25 mg SC Q2W 5.99 1.5223.69
Lutikizumab 100 mg SC Q2W 14.84 3.8057.98
Lutikizumab 200 mg SC Q2W 24.36 6.2495.05
Baseline ANC 0.19 0.120.30 <0.0001
Age <62 y 2.11 1.094.09 0.027
Female sex 2.86 1.346.10 0.007
ANC, absolute neutrophil count; OR, odds ratio; Q2W, every 2 weeks; SC, subcutaneous.
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lemental Figure 1. Study design. JSN, joint space narrowing; MRI, magnetic resonance 
imaging; Q2W, every 2 weeks; SC, subcutaneous; WOMAC, Western Ontario and McMaster 
Universities Osteoarthritis index; WORMS, Whole-Organ Magnetic Resonance Imaging Score.
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Clinical 
exam
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Analgesics
washout
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lemental Figure 2. LS mean percentage change from baseline over time for WOMAC pain 
(A) and WOMAC function . LS, least squares; Q2W, every 2 weeks; WOMAC, Western 
Ontario and McMaster Universities Osteoarthritis index. *PJ! !* vs placebo; PJ! ! vs 
placebo.
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l LS mean change from baseline over time for WOMAC pain using MI. 
LS, least squares; MI, multiple imputation; Q2W, every 2 weeks; WOMAC, Western Ontario 
and McMaster Universities Osteoarthritis index. *PJ! !* vs placebo; PJ! ! vs placebo.
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l LS mean change from baseline over time for WOMAC pain in subjects 
with positive WORMS synovitis/effusion at baseline. LS, least squares; Q2W, every 2 weeks; 
WOMAC, Western Ontario and McMaster Universities Osteoarthritis index; WORMS, Whole-
Organ Magnetic Resonance Imaging Score. *PJ! !* vs placebo; PJ! ! vs placebo.
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lemental Figure . Mean (SD) trough serum concentrations of lutikizumab over time for 
all subjects (A) and separated by presence of ADAs . ADA, anti-drug antibody; Q2W, every 
2 weeks.
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lemental Figure 64. Median absolute neutrophil counts for placebo and lutikizumab serum 
concentration quartiles at week 52 (observed cases).
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lemental Figure ; :A k
acebo or Lutikizumab. %&'bP	
'b Q2W=every 2 
weeks.
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lemental Figure . Median change from baseline over time for the biomarkers C1M (A), 
C3M , and CRPM (C), median percentage change from baseline over time in IL-6 ( , and 
mean change from baseline over time in alkaline phosphatase (E). C1M, metalloproteinase-
degraded collagen type I; C3M, metalloproteinase-degraded collagen type III; CRPM, matrix 
metalloproteinase-generated fragment of C-reactive protein; IL-6, interleukin-6; Q2W, every 2 
weeks.
-0.5
0.0
0.5
1.0
M
e
d
ia
n
 (
S
E
) 
C
h
a
n
g
e
 F
ro
m
 B
a
s
e
li
n
e
 i
n
 C
1
M
, 
n
g
/m
L
Placebo
Lutikizumab 25 mg Q2W
Lutikizumab 100 mg Q2W
Lutikizumab 200 mg Q2W
Week 4 Week 16 Week 26 Week 52Day 1
A
-0.15
-0.10
-0.05
0.00
0.05
0.10
0.15
M
e
d
ia
n
 (
S
E
) 
C
h
a
n
g
e
 F
ro
m
 B
a
s
e
li
n
e
 i
n
 C
3
M
, 
n
g
/m
L
Placebo
Lutikizumab 25 mg Q2W
Lutikizumab 100 mg Q2W
Lutikizumab 200 mg Q2W
Week 4 Week 16 Week 26 Week 52Day 1
B
Page 130 of 131
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
23
lemental Figure  continued.
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lemental Figure  continued.
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